1
|
Penault-Llorca F, Dalenc F, Chabaud S, Cottu P, Allouache D, Cameron D, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Debled M, Hardy-Bessard AC, Giacchetti S, Barthelemy P, Kaluzinski L, Mailliez A, Mouret-Reynier MA, Legouffe E, Cayre A, Martinez M, Delbaldo C, Mollon-Grange D, Macaskill EJ, Sephton M, Stefani L, Belgadi B, Winter M, Orfeuvre H, Lacroix-Triki M, Bonnefoi H, Bliss J, Canon JL, Lemonnier J, Andre F, Bachelot T. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial. ESMO Open 2024; 9:103443. [PMID: 38692082 PMCID: PMC11070798 DOI: 10.1016/j.esmoop.2024.103443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Revised: 03/15/2024] [Accepted: 04/04/2024] [Indexed: 05/03/2024] Open
Abstract
BACKGROUND The purpose of this study was to evaluate the prognostic value of the multigene EndoPredict test in prospectively collected data of patients screened for the randomized, double-blind, phase III UNIRAD trial, which evaluated the addition of everolimus to adjuvant endocrine therapy in high-risk, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. PATIENTS AND METHODS Patients were classified into low or high risk according to the EPclin score, consisting of a 12-gene molecular score combined with tumor size and nodal status. Association of the EPclin score with disease-free survival (DFS) and distant metastasis-free survival (DMFS) was evaluated using Kaplan-Meier estimates. The independent prognostic added value of EPclin score was tested in a multivariate Cox model after adjusting on tumor characteristics. RESULTS EndoPredict test results were available for 768 patients: 663 patients classified as EPclin high risk (EPCH) and 105 patients as EPclin low risk (EPCL). Median follow-up was 70 months (range 1-172 months). For the 429 EPCH randomized patients, there was no significant difference in DFS between treatment arms. The 60-month relapse rate for patients in the EPCL and EPCH groups was 0% and 7%, respectively. Hazard ratio (HR) supposing continuous EPclin score was 1.87 [95% confidence interval (CI) 1.4-2.5, P < 0.0001]. This prognostic effect remained significant when assessed in a Cox model adjusting on tumor size, number of positive nodes and tumor grade (HR 1.52, 95% CI 1.09-2.13, P = 0.0141). The 60-month DMFS for patients in the EPCL and EPCH groups was 100% and 94%, respectively (adjusted HR 8.10, 95% CI 1.1-59.1, P < 0.0001). CONCLUSIONS The results confirm the value of EPclin score as an independent prognostic parameter in node-positive, hormone receptor-positive, HER2-negative early breast cancer patients receiving standard adjuvant treatment. EPclin score can be used to identify patients at higher risk of recurrence who may warrant additional systemic treatments.
Collapse
Affiliation(s)
- F Penault-Llorca
- Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR 1240 INSERM-UCA, Clermont Ferrand.
| | - F Dalenc
- Oncopole Claudius Regaud, IUCT, Toulouse
| | | | | | | | - D Cameron
- Western General Hospital, Edinburg, UK
| | | | | | | | - M Campone
- Institut de cancérologie de l'Ouest, Saint-Herblain & Angers
| | | | | | | | - P Barthelemy
- Institut de Cancérologie Strasbourg Europe, Strasbourg
| | - L Kaluzinski
- Centre Hospitalier Cotentin, Cherbourg en Cotentin
| | | | - M-A Mouret-Reynier
- Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR 1240 INSERM-UCA, Clermont Ferrand
| | | | - A Cayre
- Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR 1240 INSERM-UCA, Clermont Ferrand
| | | | | | | | | | | | | | - B Belgadi
- Centre Hospitalier Montélimar, Montélimar, France
| | - M Winter
- Weston Park Hospital, Sheffield, UK
| | - H Orfeuvre
- Centre Hospitalier Fleyriat, Bourg-en-Bresse
| | | | | | - J Bliss
- The Institute of Cancer Research, London, UK
| | - J-L Canon
- Grand Hôpital de Charleroi, Charleroi, Belgium
| | | | - F Andre
- Gustave Roussy, Villejuif, France
| | | |
Collapse
|
2
|
Franzoi MA, Aupomerol M, Havas J, Soldato D, Lambertini M, Massarotti C, Hang H, Pistilli B, Fasse L, Tredan O, Gillanders E, Joly F, Cottu P, Mouret-Reynier MA, Tarpin C, Arnaud A, Everhard S, Martin AL, Di Meglio A, Vaz-Luis I. Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes. ESMO Open 2024; 9:102236. [PMID: 38350335 PMCID: PMC10937197 DOI: 10.1016/j.esmoop.2024.102236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 11/28/2023] [Accepted: 01/05/2024] [Indexed: 02/15/2024] Open
Abstract
BACKGROUND Sexual concerns are a major unaddressed need among survivors of breast cancer (BC) with significant negative effects on quality of life. We longitudinally analyzed sexual health over time, using patient-reported outcomes. METHODS Patients with stage I-III BC prospectively included from the CANcer TOxicity cohort (CANTO) provided data at diagnosis, then 1, 2, and 4 years afterward. Sexual concerns outcomes included poor body image (score ≤91/100), poor sexual functioning (≤16/100), poor sexual enjoyment (≤66/100), and sexual inactivity (EORTC QLQ-B23). Multivariate generalized estimating equation models assessed associations with sexual concerns after diagnosis, adjusting for age, sociodemographic, tumor, treatment, and clinical characteristics. RESULTS Nearly 78.1% among 7895 patients reported at least one sexual concern between diagnosis and 4 years' follow-up. Over time, the proportion of patients reporting sexual concerns either increased or remained constant with diagnosis. Less than half (46%, range 11.4-57) of the patients with sexual concerns reported the use of supportive care strategies, including gynecological or psychological consultations (range 11.4-57.4). Factors consistently associated with sexual concerns up to 4 years after diagnosis included already reporting the same concern at diagnosis [odds ratio (OR)poor body image 3.48 [95% confidence interval (CI) 3.11-3.89]; ORsexual inactivity 9.94 (95% CI 8.84-11.18), ORpoor sexual function 9.75 (95% CI 8.67-10.95), ORpoorsexual enjoyment 3.96 (95% CI 3.34-4.69)], endocrine therapy use [ORpoor body image 1.15 (95% CI 1.01-1.31); ORsexual inactivity 1.19 (95% CI 1.02-1.39), ORpoor sexual function 1.17 (95% CI 1.01-1.37), ORpoor sexual enjoyment 1.23 (95% CI 1.00-1.53)], and depression [ORpoor body image 2.00 (95% CI 1.72-2.34); ORsexual inactivity 1.66 (95% CI 1.40-1.97), ORpoor sexual function 1.69 (95% CI 1.43-2.00), ORpoor sexual enjoyment 1.94 (95% CI 1.50-2.51)]. Outcome-specific associations were also identified. CONCLUSIONS Sexual concerns seem frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress are commonly associated factors. A proactive evaluation of sexual health across the care continuum is needed, to promptly identify patients suitable for multidisciplinary counseling, referral, and supportive interventions.
Collapse
Affiliation(s)
- M A Franzoi
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
| | - M Aupomerol
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - J Havas
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| | - D Soldato
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| | - M Lambertini
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova; Gynecology Department, Policlinico San Martino, University of Genova, Genova; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova
| | - C Massarotti
- Physiopatology of Human Reproduction Unit, IRCCS Ospedale Policlinico San Martino, Genova; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Health (DiNOGMI department), School of Medicine, University of Genova, Genova, Italy
| | - H Hang
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| | - B Pistilli
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - L Fasse
- Interdisciplinary and Patient Pathway Department, Institut Gustave Roussy, Villejuif
| | | | - E Gillanders
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| | - F Joly
- Centre François Baclesse, Caen
| | | | | | - C Tarpin
- Institut Paoli Calmettes, Marseille
| | | | | | | | - A Di Meglio
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| | - I Vaz-Luis
- Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif
| |
Collapse
|
3
|
Allali S, Carton M, Sarrade T, Everhard S, Rivera S, Ghannam Y, Peignaux K, Guilbert P, Chara-Brunaud C, Blanchecotte J, Pasquier D, Racadot S, Bourgier C, Cottu P, Kirova Y. CANTO: Skin Toxicities Evaluation of a Multicenter Large Prospective Cohort of Irradiated Patients for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2023; 117:e163. [PMID: 37784763 DOI: 10.1016/j.ijrobp.2023.06.995] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Skin damage is a common toxicity during oncology management. Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients treated for an early breast cancer (BC). MATERIALS/METHODS CANTO (NCT01993498) is a prospective, multicentric, clinical cohort study of 11 400 patients with stage I-III BC, treated in 26 French cancer centers. In this study, we will evaluate the 8561 patients during their overall management for a BC. We are focus on specifical skin toxicities: Erythema, fibrosis, telangiectasia and skin color (CTCAE v4.0). These toxicities were assessed at 3-6 (M0), 12 (M12), 36 (M36), 60 (M60) months. RESULTS The prevalence of toxicities of interest varied over time, so at M0, 30.4% of patients had erythema while 17.7% of patients had fibrosis. At M12, M36 and M60, the prevalence of erythema decreased from 5.5 % to 2.5 % then to 2 %, respectively, while fibrosis remained stable at about 19 %. The prevalence of telangiectasia increased from 0.8 % to 7 % from M0 to M60. While the modification of skin color was 51.1 % at M0, and 10.6 % at M60. After adjustments, at M0, there was a statistically significant association between the onset of cutaneous erythema and obesity, the presence of axillary dissection, the type of surgery the age of the patient as well as the tumor phenotype RH+/HER2+ [OR: 0.79 [0.67; 0.93]]. Concerning fibrosis, a statistically significant association was found, at M12, with the age of the patient, obesity, tumor grade, Charlson score, type of surgery and mitotic index. Obesity and the age of the patient represent at M12 and M36 a risk significantly associated with the onset of telangiectasia. Concerning the modification of skin color at M12, we find a link between the age of the patient, obesity, tobacco consumption, tumor grade, Charlson score, type of surgery, and alcohol consumption [OR: 0.69 [0.51; 0.91]]. CONCLUSION In this study we identified several risk factors for acute and late skin toxicity. The knowledge of its predictive factors allows a personalized management of the patient by adapting our treatments and our monitoring according to these different factors.
Collapse
Affiliation(s)
- S Allali
- Institut Curie Paris, Paris, France
| | | | - T Sarrade
- Gustave Roussy, Cancer Campus, Villejuif, France
| | | | - S Rivera
- Gustave Roussy, Cancer Campus, Villejuif, France
| | - Y Ghannam
- Gustave Roussy, Cancer Campus, Villejuif, France
| | - K Peignaux
- Centre Georges-François Leclerc, Dijon, France
| | | | - C Chara-Brunaud
- Institut de cancérologie de Lorraine, Vandoeuvre les Nancy, France
| | - J Blanchecotte
- Institut de Cancérologie de L'ouest - Paul Papin, Angers, France
| | | | | | - C Bourgier
- Institut du Cancer de Montpellier, Montpellier, France
| | - P Cottu
- Institut Curie, Paris, France
| | | |
Collapse
|
4
|
Beddok A, Cottu P, Fourquet A, Kirova Y. [Radiotherapy and targeted therapy for the management of breast cancer: A review]. Cancer Radiother 2023; 27:447-454. [PMID: 37173174 DOI: 10.1016/j.canrad.2023.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2022] [Revised: 02/19/2023] [Accepted: 02/23/2023] [Indexed: 05/15/2023]
Abstract
The purpose of this study was to review the current knowledge regarding combinations of the most commonly used targeted therapies or those under development for the management of breast cancer with radiation therapy. Several studies have shown that the combination of radiation therapy and tamoxifen increased the risk of radiation-induced lung toxicity; therefore, the two modalities are generally not given concurrently. The combination of HER2 inhibitors (trastuzumab, pertuzumab) and radiation therapy appeared to be safe. However, trastuzumab emtansine (T-DM1) should not be given concomitantly with brain radiation therapy because this combination may increase the risk of brain radionecrosis. The combination of radiation therapy with other new targeted therapies such as new selective estrogen receptor modulators (SERDs), lapatinib, cell cycle inhibitors, immune checkpoint inhibitors, or molecules acting on DNA damage repair seems feasible but has been mainly evaluated on retrospective or prospective studies with small numbers of patients. Moreover, there is a great heterogeneity between these studies regarding the dose and fractionation used in radiotherapy, the dosage of systemic treatments and the sequence of treatments used. Therefore, the combination of these new molecules with radiotherapy should be proposed sparingly, under close monitoring, pending the ongoing prospective studies cited in this review.
Collapse
Affiliation(s)
- A Beddok
- Laboratoire d'imagerie translationnelle en oncologie (Lito), Institut Curie, université PSL, université Paris Saclay, Inserm, 91898 Orsay, France; Département de radiothérapie oncologique, institut Curie, université PSL, Centre de protonthérapie, centre universitaire, 91898 Orsay, France.
| | - P Cottu
- Département d'oncologie médicale, institut Curie, Paris, France
| | - A Fourquet
- Département de radiothérapie oncologique, institut Curie, université PSL, Paris, France
| | - Y Kirova
- Département de radiothérapie oncologique, institut Curie, université PSL, Paris, France
| |
Collapse
|
5
|
Beddok A, Porte B, Cottu P, Fourquet A, Kirova Y. [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors]. Cancer Radiother 2023; 27:240-248. [PMID: 37080859 DOI: 10.1016/j.canrad.2022.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2022] [Revised: 10/06/2022] [Accepted: 11/30/2022] [Indexed: 04/22/2023]
Abstract
Several clinical studies have shown that CDK4/6 inhibitors (CDK4/6i) improve survival in patients with metastatic or locally advanced HR-positive, HER-2-negative breast cancer (BC). The aim of this review was to synthesize the biological, preclinical and clinical aspects of the treatment of BC with CDK4/6i, with a focus on the combination of CDK4/6i and radiotherapy. The DNA damage induced after exposure of cells to ionizing radiation activates control pathways that inhibit cell progression in the G1 and G2 phases and induce a transient delay in progression in the S phase. These checkpoints are in particular mediated by cyclin-dependent kinases (CDK) 4/6 activated by cyclin D1. Several preclinical studies have shown that CDK4/6i could be used as radiosensitizers in non-small cell lung cancer, medulloblastoma, brainstem glioma and breast cancer. CDK4/6 inhibition also protected against radiation-induced intestinal toxicities by inducing redistribution of quiescent intestinal progenitor cells, making them less radiosensitive. Clinical data on the combination of CDK inhibitors and radiotherapy for both locoregional and metastatic irradiation are based on retrospective data. Nevertheless, the most optimal therapeutic sequence would be radiotherapy followed by palbociclib. Pending prospective clinical trials, the concomitant combination of the two treatments should be done under close supervision.
Collapse
Affiliation(s)
- A Beddok
- Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, 91898 Orsay, France; Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898 Orsay, France.
| | - B Porte
- Service d'oncologie médicale, GHU hôpital européen Georges-Pompidou, Paris, France
| | - P Cottu
- Département d'oncologie médicale, Institut Curie, Paris, France
| | - A Fourquet
- Institut Curie, PSL Research University, Radiation Oncology Department, Paris, France
| | - Y Kirova
- Institut Curie, PSL Research University, Radiation Oncology Department, Paris, France
| |
Collapse
|
6
|
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023; 42:1417. [PMID: 36922682 DOI: 10.1038/s41388-023-02615-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Affiliation(s)
- D Bello Roufai
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.
| | - A Gonçalves
- Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France
| | | | - S Akla
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France
| | - C Blonz
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France
| | - J Grenier
- Department of Medical Oncology, Institut du Cancer d'Avignon, Avignon, France
| | - J Gligorov
- Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France.,INSERM U938, Institut Universitaire de Cancérologie, AP-HP Sorbonne Université, Paris, France
| | - M Saghatchian
- Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France
| | - C Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - H Simon
- Department of Medical Oncology, University Hospital of Brest, Brest, France
| | - I Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Z Tharin
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - E Renaud
- Department of Medical Oncology, University Hospital of Brest, Brest, France
| | - M Bertho
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France
| | - M-A Benderra
- Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France
| | - S Delaloge
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France
| | - L Robert
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
| | - P Cottu
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - J Y Pierga
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.,Paris Cité University, Paris, France
| | - D Loirat
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - A Bertucci
- Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France
| | - B Renouf
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - F C Bidard
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.,UVSQ, Paris-Saclay University, Saint Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| |
Collapse
|
7
|
Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra MA, Delaloge S, Robert L, Cottu P, Pierga JY, Loirat D, Bertucci A, Renouf B, Bidard FC, Lerebours F. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023:10.1038/s41388-022-02585-3. [PMID: 36611120 DOI: 10.1038/s41388-022-02585-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2022] [Revised: 12/13/2022] [Accepted: 12/16/2022] [Indexed: 01/09/2023]
Abstract
SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA-mutant, hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC) patients. We report here real-life data of patients prospectively registered in the French alpelisib early access program (EAP) opened to PIK3CA-mutant HR+/HER2- ABC patients treated with alpelisib and fulvestrant. Primary endpoint was PFS by local investigators using RECIST1.1. Eleven centers provided individual data on 233 consecutive patients. Patients had received a median number of 4 (range: 1-16) prior systemic treatments for ABC, including CDK4/6 inhibitor, chemotherapy, fulvestrant and everolimus in 227 (97.4%), 180 (77.3%), 175 (75.1%) and 131 (56.2%) patients, respectively. After a median follow-up of 7.1 months and 168 events, median PFS was 5.3 months (95% CI: 4.7-6.0). Among 186 evaluable patients, CBR at 6 months was 45.3% (95% CI: 37.8-52.8). In multivariable analysis, characteristics significantly associated with a shorter PFS were age < 60 years (HR = 1.5, 95% CI = 1.1-2.1), >5 lines of prior treatments (HR = 1.4, 95% CI = 1.0-2.0) and the C420R PI3KCA mutation (HR = 4.1, 95% CI = 1.3-13.6). N = 91 (39.1%) patients discontinued alpelisib due to adverse events. To our knowledge, this is the largest real-life assessment of alpelisib efficacy. Despite heavy pre-treatments, patients derived a clinically relevant benefit from alpelisib and fulvestrant.
Collapse
Affiliation(s)
- D Bello Roufai
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.
| | - A Gonçalves
- Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France
| | | | - S Akla
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France
| | - C Blonz
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France
| | - J Grenier
- Department of Medical Oncology, Institut du Cancer d'Avignon, Avignon, France
| | - J Gligorov
- Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France.,INSERM U938, Institut Universitaire de Cancérologie, AP-HP Sorbonne Université, Paris, France
| | - M Saghatchian
- Breast Cancer Unit, American Hospital of Paris, Neuilly-sur-Seine, France
| | - C Bailleux
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - H Simon
- Department of Medical Oncology, University Hospital of Brest, Brest, France
| | - I Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - Z Tharin
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - E Renaud
- Department of Medical Oncology, University Hospital of Brest, Brest, France
| | - M Bertho
- Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Sait-Herblain and Angers, France
| | - M-A Benderra
- Department of Medical Oncology, Hôpital Tenon, AP-HP, Paris, France
| | - S Delaloge
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France
| | - L Robert
- Department of Medical Oncology, Centre Eugène Marquis, Rennes, France
| | - P Cottu
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - J Y Pierga
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.,Paris Cité University, Paris, France
| | - D Loirat
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - A Bertucci
- Aix-Marseille Univ, CNRS, INSERM, Department of Medical Oncology, Institut Paoli Calmettes, CRCM, Marseille, France
| | - B Renouf
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| | - F C Bidard
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.,UVSQ, Paris-Saclay University, Saint Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France
| |
Collapse
|
8
|
Messaoud L, Amiot HM, Lecuru F, Cottu PH, Cassou-Mounat T. Discovery of peritoneal carcinomatosis on 18F-fluorocholine PET/CT performed for primary hyperparathyroidism. Rev Esp Med Nucl Imagen Mol 2023; 42:38-39. [PMID: 36639178 DOI: 10.1016/j.remnie.2021.09.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Accepted: 09/15/2021] [Indexed: 01/15/2023]
Affiliation(s)
- L Messaoud
- Institut Curie, PSL Research University, Department of Nuclear Medicine, Paris, France.
| | - H-M Amiot
- Institut Curie, PSL Research University, Department of Nuclear Medicine, Paris, France
| | - F Lecuru
- Institut Curie, PSL Research University Breast, Gynecology and Reconstructive Surgery Unit, Paris, France; Faculté de Médecine, Université Paris Descartes, Paris, France
| | - P H Cottu
- Institut Curie, PSL Research University Department of Medical Oncology, Paris Sciences et Lettres Research University, Paris, France
| | - T Cassou-Mounat
- Toulouse Cancerology Institute, Oncopole, Department of Nuclear Medicine, Toulouse, France
| |
Collapse
|
9
|
Courtinat F, Cottu P, Féron JG, Jehanno N, Fourquet A, Kirova Y, Beddok A. Multidisciplinary management and role of reirradiation in the treatment of a breast cancer patient with four locoregional recurrences. Cancer Radiother 2022; 27:154-157. [PMID: 36041968 DOI: 10.1016/j.canrad.2022.07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 07/07/2022] [Accepted: 07/09/2022] [Indexed: 10/15/2022]
Abstract
Breast cancer is a frequent and sometimes fatal disease. The risk of locoregional recurrence has considerably decreased since the introduction of adjuvant treatments (radiotherapy, chemotherapy, hormone therapy). Nevertheless, some patients present a risk of multiple local recurrences. We report here the case of a patient who had four locoregional breast cancer recurrences. There is currently no validated biomarker that allows the prediction of recurrence. Salvage surgery, most often mastectomy, remains the recommended treatment for the management of these recurrences in the irradiated field. However, increasingly, depending on the patient's wishes and the technical possibilities of multiple surgeries, the question of a second conservative treatment and reirradiation arises. This type of management must in all cases be multidisciplinary and in specialized centers. Reirradiation must in any case try to give maximum priority to the protection of healthy tissue already irradiated.
Collapse
Affiliation(s)
- F Courtinat
- Radiation Oncology Department, institut Curie, 25 rue d'Ulm, Paris, France
| | - P Cottu
- Medical Oncology Department, institut Curie, Paris France
| | - J-G Féron
- Surgical Oncology Department, institut Curie, Paris France
| | - N Jehanno
- Nuclear Medicine Department, institut Curie, Paris France
| | - A Fourquet
- Radiation Oncology Department, institut Curie, 25 rue d'Ulm, Paris, France
| | - Y Kirova
- Radiation Oncology Department, institut Curie, 25 rue d'Ulm, Paris, France
| | - A Beddok
- Radiation Oncology Department, institut Curie, 25 rue d'Ulm, Paris, France.
| |
Collapse
|
10
|
Konecny GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, Fasching PA, Feisel-Schwickardi G, Poelcher M, Roman LD, Rody A, Karlan BY, Mullany SA, Chen H, Ray-Coquard IL, Provencher DM, Yachnin A, Cottu PH, Glaspy JA, Haluska P, Slamon DJ. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. Gynecol Oncol 2021; 163:465-472. [PMID: 34642026 DOI: 10.1016/j.ygyno.2021.09.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Revised: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 12/28/2022]
Abstract
PURPOSE Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC. DESIGN Patients were randomly assigned to receive CP/ganitumab (18 mg/kg q3w) or CP/placebo for 6 cycles followed by 6 cycles of single agent ganitumab/placebo maintenance therapy as front-line therapy. Primary endpoint was progression free survival. Secondary endpoints were time to progression and overall survival. Pretreatment samples were prospectively collected for retrospective biomarker analyses. RESULTS 170 patients enrolled. 165 patients assessable for toxicity. Median PFS was 15.7 months with CP/ganitumab and 16.7 months with CP/placebo (HR 1.23; 95% CI 0.82-1.83, P = 0.313). All grade neutropenia (84.1% vs 71.4%), thrombocytopenia (75.3% vs 57.1%) and hyperglycemia (15.9% vs 2.6%) were more common in the ganitumab group compared to the placebo group. Ganitumab/placebo related serious adverse events were reported in 26.1% of the patients with ganitumab and in 6.5% with placebo. Non-progression related fatal events were more common with ganitumab (5 versus 2 patients). The ganitumab group experienced more dose delays which resulted in lower relative dose intensity of chemotherapy in the experimental group. In an exploratory model IGFBP2 expression was predictive of ganitumab response (treatment interaction; PFS, P = 0.03; OS, P = 0.01). CONCLUSION Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients.
Collapse
Affiliation(s)
- G E Konecny
- Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA; Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA.
| | | | - T M Davidson
- Division of Oncology Mayo Clinic, Rochester, MN, USA
| | - B J Winterhoff
- Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
| | - S Ma
- Institute for Health Informatics, School of Medicine, University of Minnesota, Minneapolis, MN, USA
| | - S Mahner
- Department of Gynecology and Gynecologic Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - J Sehouli
- University Hospital Charite, Campus Virchow-Klinikum, Klinik für Frauenheilkunde und Geburtshilfe & Nord-Ostdeutsche-Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany
| | - P A Fasching
- Department of Obstetrics and Gynecology, University of Erlangen, Erlangen, Germany
| | | | - M Poelcher
- Department of Gynecology, Rotkreutzklinikum, Munich, Germany
| | - L D Roman
- USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - A Rody
- Department of Obstetrics and Gynecology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany
| | - B Y Karlan
- Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, USA
| | - S A Mullany
- Department of Obstetrics and Gynecology, University of Minnesota, Minneapolis, MN, USA
| | - H Chen
- Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA
| | | | | | - A Yachnin
- Department of Oncology, Kaplan Medical Center, Rehovot, Israel
| | | | - J A Glaspy
- Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA
| | - P Haluska
- Bristol-Myers Squibb Inc, Lawrenceville, NJ, USA
| | - D J Slamon
- Division of Hematology/Oncology, University of California Los Angeles, Los Angeles, CA, USA
| |
Collapse
|
11
|
Bachelot T, Dalenc F, Chabaud S, Cottu P, Allouache D, Brain E, Jacquin JP, Grenier J, Venat Bouvet L, Brunt M, Campone M, Del Piano F, Debled M, Hardy Bessard AC, Giacchetti S, Bliss J, Canon JL, Lemonnier J, Cameron D, André F. Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.04.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
12
|
Porte B, Carton M, Lerebours F, Brain E, Loirat D, Haroun L, Bellesoeur A, Bach Hamba S, Kirova Y, Cottu P. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. Breast 2020; 54:303-310. [PMID: 33242757 PMCID: PMC7695984 DOI: 10.1016/j.breast.2020.11.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 11/11/2020] [Accepted: 11/12/2020] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Palbociclib is indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), in combination with endocrine therapy. Emerging real-life data suggest that the efficacy of a palbociclib-based therapy is highly conserved. We report the Institut Curie hospital experience. PATIENTS AND METHODS We retrospectively reviewed all patients with HR + HER2- ABC treated with a palbociclib-based therapy as first or second line for ABC, with an initial prescription from November 2016 to December 2018. Clinical, laboratory and imaging data were retrieved from electronic records. Data lock was December 31st, 2019. Descriptive analyses, univariate and multivariate Cox regression analyses were performed. RESULTS We included 310 consecutive patients. Median age was 61.8 years old. Palbociclib was prescribed in first line in 225 patients (72.6%). Before palbociclib-based therapy initiation, 122 patients (39.3%) were endocrine naive, 96 (31.0%) endocrine sensitive and 92 (29.7%) endocrine resistant. Median follow-up was 20.7 months. Median progression free survival (PFS) was 23.4 months (95%CI: 21.6-NR) in endocrine naive patients, 22.7 months (95%CI: 14.7-NR) in endocrine sensitive, and 13.4 months (95%CI: 10.7-20.8) in endocrine resistant. At 12 months from the initiation of palbociclib, 94.5% of patients were alive. By multivariate analysis, poor prognosis factors for PFS were identified in the endocrine naive/sensitive population: initial ECOG status 2, previous endocrine therapy for ABC, 3 metastatic sites or more. Toxicity profile was similar to previously published data. CONCLUSION In a non-selected population of patients with HR + HER2- ABC, the efficacy and safety data are strikingly similar to those previously reported.
Collapse
Affiliation(s)
- B Porte
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - M Carton
- Department of Biostatistics, Institut Curie, Paris and Saint Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - E Brain
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - D Loirat
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - L Haroun
- Department of Data, Institut Curie, Paris and Saint Cloud, France
| | - A Bellesoeur
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - S Bach Hamba
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France
| | - Y Kirova
- Department of Radiation Oncology, Institut Curie, Paris and Saint Cloud, France
| | - P Cottu
- Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.
| |
Collapse
|
13
|
Djehal N, Havas J, Gbenou A, Martin E, Charles C, Dauchy S, Pistilli B, Cadeau C, Arveux P, Everhard S, Lemonnier J, Coutant C, Cottu P, Lesur A, Menvielle G, Dumas A, Andre F, Michiels S, Vaz-Luis I, Di Meglio A. Use of oral complementary-alternative medicine (OCAM) and fatigue among early breast cancer (BC) patients (pts). Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30780-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Cottu P, Livartoswki A, Pérol D, Trédan O, Gilberg M, Ghorbal R, Dupin J, Maillard C. KADor – Étude rétrospective française visant à décrire la prise en charge thérapeutique des patientes présentant un cancer du sein précoce HER2+ ayant bénéficié d’un traitement néoadjuvant à base d’Herceptin®. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
15
|
Ferreira AR, Di Meglio A, Pistilli B, Gbenou AS, El-Mouhebb M, Dauchy S, Charles C, Joly F, Everhard S, Lambertini M, Coutant C, Cottu P, Lerebours F, Petit T, Dalenc F, Rouanet P, Arnaud A, Martin A, Berille J, Ganz PA, Partridge AH, Delaloge S, Michiels S, Andre F, Vaz-Luis I. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol 2020; 30:1784-1795. [PMID: 31591636 DOI: 10.1093/annonc/mdz298] [Citation(s) in RCA: 128] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus CT on the quality of life (QoL) of early BC patients is unknown. Here, we characterize the independent contribution of ET and CT on patient-reported outcomes (PROs) at 2 years after diagnosis. PATIENTS AND METHODS We prospectively collected PROs in 4262 eligible patients using the European Organization for Research and Treatment of Cancer QLQ-C30/BR23 questionnaires inside CANTO trial (NCT01993498). The primary outcome was the C30 summary score (C30-SumSc) at 2 years after diagnosis. RESULTS From eligible patients, 37.2% were premenopausal and 62.8% postmenopausal; 81.9% received ET and 52.8% CT. In the overall cohort, QoL worsened by 2 years after diagnosis in multiple functions and symptoms; exceptions included emotional function and future perspective, which improved over time. ET (Pint = 0.004), but not CT (Pint = 0.924), had a persistent negative impact on the C30-SumSc. In addition, ET negatively impacted role and social function, pain, insomnia, systemic therapy side-effects, breast symptoms and further limited emotional function and future perspective recovery. Although CT had no impact on the C30-SumSc at 2-years it was associated with deteriorated physical and cognitive function, dyspnea, financial difficulties, body image and breast symptoms. We found a differential effect of treatment by menopausal status; in premenopausal patients, CT, despite only a non-significant trend for deteriorated C30-SumSc (Pint = 0.100), was more frequently associated with QoL domains deterioration than ET, whereas in postmenopausal patients, ET was more frequently associated with QoL deterioration, namely using the C30-SumSc (Pint = 0.004). CONCLUSION(S) QoL deterioration persisted at 2 years after diagnosis with different trajectories by treatment received. ET, but not CT, had a major detrimental impact on C30-SumSc, especially in postmenopausal women. These findings highlight the need to properly select patients for adjuvant ET escalation.
Collapse
Affiliation(s)
- A R Ferreira
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France; Breast Unit, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal
| | - A Di Meglio
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France
| | - B Pistilli
- Medical Oncology, Gustave Roussy, Cancer Campus, Villejuif
| | - A S Gbenou
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France
| | - M El-Mouhebb
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France
| | - S Dauchy
- Department of Supportive Care, Gustave Roussy, Cancer Campus, Villejuif
| | - C Charles
- Department of Supportive Care, Gustave Roussy, Cancer Campus, Villejuif
| | - F Joly
- Medical Oncology, Centre François Baclesse Caen, Caen
| | | | - M Lambertini
- Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy
| | - C Coutant
- Surgical Oncology, Centre Georges-François Leclerc, Dijon
| | - P Cottu
- Medical Oncology, Institut Curie, Paris
| | - F Lerebours
- Medical Oncology, Institut Curie, Hôpital René Huguenin, Saint-Cloud
| | - T Petit
- Department of Medicine, Paul Strauss Cancer Center and University of Strasbourg, Strasbourg
| | - F Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer - Oncopole, Toulouse
| | - P Rouanet
- Surgical Oncology, C.R.L.C Val d'Aurelle, Montpellier
| | - A Arnaud
- Radiotherapy Department, Clinique Sainte Catherine Avignon, Avignon
| | | | - J Berille
- Ministry of Higher Education and Research, Ministere de l'Enseignement Superieur et de la Recherche, Paris, France
| | - P A Ganz
- Medical Oncology, Ronald Reagan UCLA Medical Center, Los Angeles
| | - A H Partridge
- Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - S Delaloge
- Medical Oncology, Gustave Roussy, Cancer Campus, Villejuif
| | - S Michiels
- Service de Biostatistique et d'Epidémiologie, Gustave Roussy, University Paris-Sud, University Paris-Saclay, Villejuif; CESP, INSERM, U1018 ONCOSTAT, Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France
| | - F Andre
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France; Medical Oncology, Gustave Roussy, Cancer Campus, Villejuif
| | - I Vaz-Luis
- INSERM Unit 981, Gustave Roussy, Cancer Campus, Villejuif, France; Medical Oncology, Gustave Roussy, Cancer Campus, Villejuif.
| |
Collapse
|
16
|
Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol 2019; 29:2334-2340. [PMID: 30307466 DOI: 10.1093/annonc/mdy448] [Citation(s) in RCA: 88] [Impact Index Per Article: 17.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. Patients and methods NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)×3 21-day courses followed by docetaxel 100 mg/m2×3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety. Results Overall, 106 patients were randomised [median Prosigna® ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7.7% (95% CI 0.4-14.9)] and chemotherapy [15.7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm). Conclusion LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna®-defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less favourable safety profile. LETPAL combination might represent an alternative to chemotherapy in early high-risk LBC. Clinical Trial Number NCT02400567.
Collapse
Affiliation(s)
- P Cottu
- Department of Medical Oncology, Institut Curie, Paris, France; Paris Sciences et Lettres University, Paris, France.
| | - V D'Hondt
- Department of Medical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France
| | - S Dureau
- Department of Biometry, Institut Curie, Saint-Cloud, France
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Saint-Cloud, France
| | - I Desmoulins
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
| | - P-E Heudel
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France
| | - F P Duhoux
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - C Levy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - M-A Mouret-Reynier
- Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France
| | - F Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Toulouse, France
| | - J-S Frenel
- Department of Medical Oncology, ICO Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France
| | - C Jouannaud
- Department of Medical Oncology, Institut Jean Godinot, Reims, France
| | - L Venat-Bouvet
- Department of Medical Oncology, Limoges University Hospital, Limoges, France
| | - S Nguyen
- Department of Medical Oncology, Centre Hospitalier de Pau, Pau, France
| | - J-M Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | - J-L Canon
- Department of Oncology-Hematology, Grand Hôpital de Charleroi, Charleroi, Belgium
| | - J Grenier
- Department of Medical Oncology, Institut Sainte-Catherine, Avignon, France
| | - C Callens
- Paris Sciences et Lettres University, Paris, France; Pharmacogenomics, Department of Tumor Biology, France
| | - D Gentien
- Paris Sciences et Lettres University, Paris, France; Genomics Platforms, Translational Research Department, Institut Curie, Paris, France
| | | | - A Vincent-Salomon
- Paris Sciences et Lettres University, Paris, France; Tumour Biology Department, Institut Curie, Paris, France
| | - S Delaloge
- Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
17
|
Ring A, Borstnar S, Ferreira A, Azim HA, Cottu P, Lu J, Martin M, Zamagni C, Beck JT, Zhou K, Wu J, Menon L, De Laurentiis M. Abstract P6-18-16: Ribociclib (RIBO) + letrozole (LET) in older patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The cyclin-dependent kinase (CDK)4/6 inhibitor RIBO is approved in combination with an aromatase inhibitor (AI) for HR+, HER2– ABC in postmenopausal women with no prior therapy for ABC, based on the MONALEESA-2 trial (Hortobagyi et al. NEJM 2016). Although a high proportion of patients with HR+, HER2– ABC are >65 years of age, older patients are often under-represented in clinical trials. Furthermore, treatment decisions may be complicated by comorbidities, functional status, and concurrent medications. Here, we report early safety results for patients ≥65 years of age enrolled in CompLEEment-1, an open-label, phase 3b trial evaluating RIBO+LET as first-line endocrine-based therapy in an expanded patient population.
Methods: Patients with HR+, HER2– ABC, ≤1 line of prior chemotherapy (CT), and no prior endocrine therapy for ABC received RIBO (600 mg/day, 3 weeks on/1 week off) + LET (2.5 mg/day); men and premenopausal women received concomitant goserelin (3.6-mg subcutaneous implant every 28 days). The primary outcome was safety and tolerability. A pre-planned interim analysis was conducted ˜15 months after first patient first visit.
Results: Of the first 1,008 patients enrolled who completed 56 days of follow-up or discontinued before the data cut-off date, 377 were ≥65 years of age. Of these, 157 (41.6%) were 65-<70 years, 107 (28.4%) were 70-<75 years, and 113 (30%) were ≥75 years. The majority of patients (94.4%) had an Eastern Cooperative Oncology Group performance status ≤1; 33.2% presented with stage IV disease at diagnosis; 9 patients were male. The most common sites of metastasis were bone (70.0%), lung (44.8%), and lymph nodes (29.7%). The most common all-grade adverse events (AEs) were neutropenia (58.4%), nausea (31.8%), and fatigue (24.1%). The most common grade 3/4 AEs were neutropenia (37.7%) and alanine aminotransferase increase (4.2%). QT prolongation events were mild (majority grade 1/2) and occurred in 6.1% of patients (0.5% grade 3/4). Dose reduction or interruption due to AEs occurred in 54.5% of patients; 6.9% of patients had AEs leading to treatment discontinuation. In the overall patient population, the most frequent grade 3/4 AEs were neutropenia (42.8%), leukopenia (3.4%), and increased alanine aminotransferase (2.9%); QT prolongation occurred in 5.4% of patients (0.5% grade 3/4).
Conclusions: Initial safety results from CompLEEment-1, from the first 56 days of follow-up, demonstrate the tolerability of RIBO+LET in older patients, consistent with the overall patient population. NCT02941926.
Citation Format: Ring A, Borstnar S, Ferreira A, Azim HA, Cottu P, Lu J, Martin M, Zamagni C, Beck JT, Zhou K, Wu J, Menon L, De Laurentiis M. Ribociclib (RIBO) + letrozole (LET) in older patients with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Preliminary subgroup results from the phase 3b CompLEEment-1 trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-16.
Collapse
Affiliation(s)
- A Ring
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - S Borstnar
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - A Ferreira
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - HA Azim
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - P Cottu
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - J Lu
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - M Martin
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - C Zamagni
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - JT Beck
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - K Zhou
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - J Wu
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - L Menon
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| | - M De Laurentiis
- Royal Marsden NHS Foundation Trust, Surrey, United Kingdom; Institute of Oncology Ljubljana, Ljubljana, Slovenia; Instituto Português de Oncologia do Porto, Porto, Portugal; Cairo University, Cairo, Egypt; Institut Curie, Paris, France; University of Southern California, Los Angeles, CA; Instituto de Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain; Addarii Medical Oncology Unit, S. Orsola-Malpighi Hospital, Bologna, Italy; Highlands Oncology Group, Fayetteville, AR; Novartis Pharmaceuticals, East Hanover, NJ; National Cancer Institute “Fondazione Pascale”, Napoli, Italy
| |
Collapse
|
18
|
Bidard FC, Jacot W, Dureau S, Brain E, Bachelot T, Bourgeois H, Goncalves A, Ladoire S, Naman H, Dalenc F, Gligorov J, Espie M, Levy C, Ferrero JM, Loirat D, Cottu P, Dieras V, Simondi C, Berger F, Alix-Panabieres C, Pierga JY. Abstract GS3-07: Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-gs3-07] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In ER+ HER2- metastatic breast cancer (MBC) patients, the clinical choice between 1st line hormone therapy (HT, the recommended option) or chemotherapy (CT) is based on the absence of “visceral crisis” or adverse prognostic factors, with no proven/objective criteria. In that context, STIC CTC (NCT01710605) was set up as a strategy trial to test whether circulating tumor cells (CTC) count could help customize the choice between 1st line HT or CT.
Methods: For this multicenter phase 3 non-inferiority trial, the main inclusion criteria were: ER+ HER2- MBC with no prior therapy, PS≤2, no contra-indication to HT or CT and informed consent. The a priori treatment choice (HT or CT) and CTC count (CellSearch®) were obtained in all patients prior to randomization. Patients were randomized 1:1 between clinically-driven choice (CTC count not disclosed, HT or CT administered as decided a priori), or a CTC-driven choice (HT if <5 CTC/7.5ml, CT if ≥5 CTC/7.5ml). The primary objective was treatment efficacy (PFS hazard ratio), non-inferiority being established if the upper bound of the PFS HR 2-sided 90%CI is ≤1.25; secondary objectives included subgroup analyses (CTC status, patient characteristics) and OS.
Results: 761 MBC patients were randomized between 02/2012 and 08/2016. Baseline characteristics: 7.8% of patients had a PS=2, 24.1% had a de novo metastatic disease; 63.3% received prior adjuvant HT and 49.9% prior adjuvant CT; 31.3% had ≥3 metastatic sites. A priori treatments (HT or CT) and CTC count (< or ≥5 CTC/7.5ml) were well balanced between the two arms. After randomization, in the clinically-driven arm, N=267 (72.4%) patients received HT and N=102 (27.6%) CT (as decided a priori). In the CTC-driven arm: (1) the a priori choice of HT was confirmed by a low CTC count in N=181 (67.5%) of patients, while N=87 (32.5%) were switched to CT due to a high CTC count; (2) the a priori choice of CT was confirmed by high CTC count in only N=48 (48%) patients, while N=52 (52%) were switched to HT. The primary endpoint was met, PFS being not inferior in the CTC-driven arm (HR=0.98, 90%CI=[0.84–1.13]). Analyses focusing on discordant subgroups showed that for patients with a priori choice of HT but with high CTC count (leading to a switch to CT in the CTC-arm), PFS was significantly longer in the CTC-driven arm than in the standard arm (HR=0.67, 95%CI=[0.49–0.92]; p=0.01), with a non-significant trend toward longer OS (HR=0.68, 95%CI=[0.44–1.07]; p=0.09). Inversely, for patients with a priori choice of CT but with low CTC count (i.e. de-escalation to HT in the CTC arm), PFS was not statistically different between the two arms.
Conclusion: This trial demonstrates the clinical utility of CTC count as an objective decision tool when considering 1st line therapy in ER+ HER2- MBC. In most patients, CTC count did confirm the a priori clinical choice; however, trial results show that in discrepant cases, CTC count may be trusted for either escalating (i.e. considering CT in patients if high CTC count) or de-escalating (i.e. considering HT in patients if low CTC count) 1st line therapy.
Funding: French National Cancer Institute; Menarini Silicon Biosystems.
Citation Format: Bidard F-C, Jacot W, Dureau S, Brain E, Bachelot T, Bourgeois H, Goncalves A, Ladoire S, Naman H, Dalenc F, Gligorov J, Espie M, Levy C, Ferrero J-M, Loirat D, Cottu P, Dieras V, Simondi C, Berger F, Alix-Panabieres C, Pierga J-Y. Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr GS3-07.
Collapse
Affiliation(s)
- F-C Bidard
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - W Jacot
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - S Dureau
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - E Brain
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - T Bachelot
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - H Bourgeois
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - A Goncalves
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - S Ladoire
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - H Naman
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - F Dalenc
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - J Gligorov
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - M Espie
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - C Levy
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - J-M Ferrero
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - D Loirat
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - P Cottu
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - V Dieras
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - C Simondi
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - F Berger
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - C Alix-Panabieres
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| | - J-Y Pierga
- Institut Curie, Paris & Saint Cloud, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Léon Bérard, Lyon, France; Clinique Victor Hugo, Le Mans, France; Institut Paoli Calmette, Marseille, France; Centre Georges Francois Leclerc, Dijon, France; Centre Azuréen de Cancérologie, Mougins, France; IUCT, Toulouse, France; Hôpital Tenon (AP-HP), Paris, France; Hôpital Saint Louis (AP-HP), Paris, France; Centre Francois Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Centre Eugène Marquis, Rennes, France; Montpellier University Hospital, Montpellier, France
| |
Collapse
|
19
|
Tille JC, Saint Martin C, Fuhrmann L, De Koning L, Reyal F, Piccart M, Kirova Y, Cottu P, Carton M, Vincent Salomon A. Abstract P4-02-04: Tumor-infiltrating lymphocytes in invasive lobular breast cancer identify a poor prognostic sub-group. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-02-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Tumor infiltrating lymphocytes (TILs) are associated with an improved outcome in triple negative and HER2 breast cancers. Conversely, a recent pioneer study showed that TILs in infiltrating lobular carcinoma (ILC) were associated with a worse prognosis. We aimed at assessing the prognostic impact of TILs in a large cohort of primary surgically treated ILC with a long follow-up in a single institution.
Methods:
We retrospectively reviewed 459 ILC treated at the Curie Institute between 2005 and 2008. Clinico-pathological patients' characteristics were collected and all archived tumor slides were centrally reviewed for TILs quantification. We analyzed stromal TILs scored as a continuous variable. Cox analyses were performed for relapse free survival (RFS) and for overall survival (OS), and chi-square and Fisher test were performed to evaluate the correlation between TILs and other clinico-pathological variables. For statistical analyses, presence or absence of TILs was considered.
Results:
Patients had a mean age of 60.3 years and a median follow-up of 8.8 years, during which 74 local and/or distant relapse events occurred, among which 37 deaths due to the disease. The presence of TILs were significantly associated with greater tumor size (pT), positive nodal status (pN), molecular class (HER2 amplified), and specific morphological nuclear features such as high nuclear grade, multinucleation, macronucleoli and high Nottingham Prognostic Index class. Presence of intra-tumoral lymphocytes is significantly associated with a worse RFS (HR: 2.07 p=0.003) and OS (HR: 4.58 p<0.001) in a multivariate analysis, independently of chemotherapy.
Relapse Free Survival TILs% (IC 95%)% (IC 95%)No95.3 (92.5-98.2)89.0 (84.3-94.0)Yes89.3 (85.1-93.6)74.0 (67.5-81-1)
Overall Survival OS at 5 yearsOS at 10 yearsTILs% (IC 95%)% (IC 95%)No99.5 (97.8-100)95.8 (92.3-99.4)Yes95.3 (92.3-98.1)83.5 (77.8-89.7)
Conclusion:
TILs are an independent prognostic factor associated with a poor outcome in ILC that are easy to assess on diagnostic biopsies. In order to elucidate the role of TILs in ILC, we will further characterize the immune infiltrate and integrate these results with DNA, RNA and protein analyses of the same carcinomas, in order to gain insight into their molecular features and to facilitate the identification of new therapeutic strategies for these ILC with TILs.
Citation Format: Tille J-C, Saint Martin C, Fuhrmann L, De Koning L, Reyal F, Piccart M, Kirova Y, Cottu P, Carton M, Vincent Salomon A. Tumor-infiltrating lymphocytes in invasive lobular breast cancer identify a poor prognostic sub-group [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-02-04.
Collapse
Affiliation(s)
- J-C Tille
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - C Saint Martin
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - L Fuhrmann
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - L De Koning
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - F Reyal
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - M Piccart
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - Y Kirova
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - P Cottu
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - M Carton
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| | - A Vincent Salomon
- University Hospital Geneva, Geneva, Switzerland; PSL Research University, Saint-Cloud, France; Institut Curie, Paris, France; Insitut Jules Bordet, Bruxelles, Belgium
| |
Collapse
|
20
|
Monneur A, Bertucci F, Lardy-Cleaud A, Augereau P, Debled M, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Bachelot T, Ferrero JM, Guiu S, Uwer L, Campone M, Cottu P, Jouannaud C, De la Motte Rouge T, Leheurteur M, Petit T, Pistilli B, Dalenc F, Simon G, Robain M, Viens P, Lerebours F, Gonçalves A. Abstract P5-17-04: Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-17-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:Primary inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. Survival of IBC patients has been improved by multimodal therapy. However 5-year overall survival (OS) still remains close to 50-60%, due to high risk of disseminated disease. Given the low incidence, prognosis of metastatic cases stages is poorly described.
Methods:This study aimed to describe OS of IBC (T4d AJCC TNM classification) with upfront or recurrent metastatic disease compared with non-IBC patients in the ESME database (N=16,702 patients). OS was calculated from the diagnosis of metastasis to the date of death (from any cause), or censored to date of latest news. Secondary objectives included progression-free survival (PFS).
Results:From 2008 to 2014, 7,465 patients with diagnosis of MBC and known clinical status of their primary tumor (T) were identified, including 582 IBC (T4d) and 6,883 non-IBC. As expected, metastatic IBC was associated with pejorative features compared to non-IBC, with less hormonal receptors-positive tumors (44% vs 65.6%), more HER2-positive (30% vs 18.6%) or triple-negative (25.9% vs 15.8%) cases (p<0.001), more frequent upfront M1 stage (53.3% vs 27.7%; p<0.001), and shorter median disease-free interval (2.02 years vs. 4.9 years; p<0.001). With a median follow-up of 50.2 months (0-104), median OS was 28.4 [95%CI 24-33.8] versus 37.2 months [95%CI 36.1-38.5] in metastatic IBC and non-IBC cases respectively (p<0.0001, log-rank test). By multivariate Cox model with adjustment for major prognostic factors [including age, disease-free interval, type of relapse, visceral metastases, molecular subtype, grade], OS was significantly shorter in the metastatic IBC group compared with non-IBC group (HR 1.25 [95%CI 1.1-1.4], p=0.0002). Of note, survival of metastatic IBC patients improved over the last years: median OS 24 months [95%CI 20-31.9], 29 months [95%CI 21.7-39.9] and 36 months [95%CI 27.9-NE] if diagnosed before 2011, between 2011 and 2012, or after 2012 respectively (p=0.003). Such improvement was not observed in non-IBC patients. IBC was associated with shorter median PFS under first line systemic treatment compared with non-IBC (7.2 months [95%CI 6.6-8.3] vs 9.5 months [95%CI 9.1-9.8] respectively, p=0.0136). This was maintained in a multivariate Cox model adjusting for same factors as for OS (HR 1.15 [95%CI 1-1.3], p=0.0050).
Compared with non-IBC, synchronous metastatic IBC showed worse median OS and PFS (39.9 months [95%CI 34.2-45.3] vs 48.4 months [95%CI 46.3-50.8], p=0.0035; 10 months [95%CI 8.8-12.7] vs 14.5 months [95%CI 13.6-15.7], p=0.0027, respectively. Similar results were obtained in metachronous metastatic cases (20.01 months [95%CI 17.1-21.2] vs 32.8 months [95%CI 31.5-34.3], p<0.0001; 5.1 months [95%CI 4.1-6] vs 7.9 months [95%CI 7.6-8.3], p<0.0001, respectively).
Conclusion:In this large national and multicentric study, IBC is a major and independent factor associated with adverse outcome in metastatic setting. Of note, the independent adverse impact on PFS identified in this study may suggest a lower sensitivity of metastatic IBC to available therapeutics. However, results seem to improve in the last years. Detailed analysis according to phenotype will be available.
Citation Format: Monneur A, Bertucci F, Lardy-Cleaud A, Augereau P, Debled M, Levy C, Mouret-Reynier MA, Coudert B, Mailliez A, Bachelot T, Ferrero J-M, Guiu S, Uwer L, Campone M, Cottu P, Jouannaud C, De la Motte Rouge T, Leheurteur M, Petit T, Pistilli B, Dalenc F, Simon G, Robain M, Viens P, Lerebours F, Gonçalves A. Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-17-04.
Collapse
Affiliation(s)
- A Monneur
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Bertucci
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Lardy-Cleaud
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Augereau
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Debled
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - C Levy
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - MA Mouret-Reynier
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - B Coudert
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Mailliez
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T Bachelot
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - J-M Ferrero
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - S Guiu
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - L Uwer
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Campone
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Cottu
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - C Jouannaud
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T De la Motte Rouge
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Leheurteur
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - T Petit
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - B Pistilli
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Dalenc
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - G Simon
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - M Robain
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - P Viens
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - F Lerebours
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| | - A Gonçalves
- Institut Paoli-Calmettes, Marseille, France; Centre Léon Bérard - Biometrics Unit, Lyon, France; Institut de Cancérologie de l'Ouest, Angers, France; Institut Bergonié, Bordeaux, France; Centre François Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Centre Georges François Leclerc, Dijon, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre Antoine Lacassagne, Nice, France; Institut du Cancer de Montpellier, Montpellier, France; Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France; Institut de Cancérologie de l'Ouest, Nantes St-Herblain, France; Institut Curie, Paris & Saint-Cloud, France; Institut de Cancérologie Jean-Godinot, Reims, France; Centre Eugéne Marquis, Rennes, France; Centre Henri Becquerel, Rouen, France; Centre Paul Strauss, Strasbourg, France; Institut Gustave Roussy, Villejuif, France; Institut Claudius Regaud – IUCT Oncopole, Toulouse, France; Unicancer, Paris, France
| |
Collapse
|
21
|
Clément-Zhao A, Tanguy ML, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. Abstract P3-12-06: TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-12-06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background and Purpose: Recent phase 3 clinical trials have evaluated the addition of bevacizumab (B) to standard chemotherapy in the treatment of patients with non-metastatic breast cancer. But few data are available about the tolerance of B with locoregional radiation therapy (RT). The objective was to evaluate the 5 years late toxicities of the concurrent B and RT in non-metastatic breast cancer.
Material and methods: This is a multicenter prospective study including non-metastatic breast cancer patients enrolled in phase 3 clinical trials evaluating B with concurrent RT (BEATRICE, BETH, BEVERLY 1, BERVERLY 2) versus RT alone. All patients received neo-adjuvant or adjuvant chemotherapy and normo-fractionated breast or chest wall RT, with or without regional lymph nodes RT. B was administrated as an equivalent of 5 mg/kg every week for 1 year. The safety profile (using the Common Terminology Criteria for Adverse Events version 3.0) was evaluated at 1, 3 and 5 years after the completion of radiotherapy.
Results: From October 2007 to January 2012, 151 patients totally included. Median follow-up was 60 months (36-84) and 5 years late toxicities were available for 104 patients (46 with B and RT, 58 with RT alone). Median age was 51 (22-81). 61% of patients received regional lymph nodes RT. The majority of tumor was triple negative (65.6%), tumor size <2cm (50%) and nodal status negative (63.8%). Median total dose of B was 15000 mg (13200 – 18550) and median duration was 11.2 months (11-12.6). No grade ≥3 toxicity was observed. Only 16 patients had grade 1-2 toxicities (8 treated with B and RT, 8 with RT alone): n=4 (3.8%) had grade 1 pain, n=5 (4.8%) had grade 1-2 fibrosis, n=1 (1%) had grade 2 telangiectasia and n=5 (4.8%) had grade 1-2 lymphoedema. No significant difference between the 2 arms was observed. One patient of 46 evaluated had Left Ventricular Ejection Fraction inferior to 50%. At 5 years, overall survival was 93.8%, disease free-survival 89% and locoregional free-survival 93.1 %.
Conclusion: Concurrent B and locoregional RT provides acceptable 5-years toxicities in patients with non-metastatic breast cancer. No grade ≥3 toxicity was observed.
Citation Format: Clément-Zhao A, Tanguy M-L, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-06.
Collapse
Affiliation(s)
- A Clément-Zhao
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - M-L Tanguy
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Cottu
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - B De La Lande
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Bontemps
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - C Lemanski
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - P Baumann
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - C Levy
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - K Peignaux
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - A Reynaud-Bougnoux
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - A Gobillion
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| | - Y Kirova
- Institut Curie, Paris, France; Institut Régional du Cancer de Montpellier, Montpellier, France; Centre François Baclesse, Caen, France; CHU Jean Minjoz, Besançon, France; Centre d'Oncologie de Gentilly, Nancy, France; Centre Georges-François Leclerc, Dijon, France; CHU Tours, Tours, France
| |
Collapse
|
22
|
Baker JL, Di Meglio A, El Mouhebb M, Iyengar NM, Michiels S, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz Luis I, Jones LW. Abstract P1-15-03: Association between exercise, pathological complete response, and treatment tolerability in patients receiving neoadjuvant chemotherapy for operable breast cancer: Results from the CANTO study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-15-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Randomized trials, although not all, suggest exercise therapy improves treatment completion rates / relative dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy (CT). In addition, preclinical studies show that exercise therapy adds to the antitumor activity of standard CT in murine models of breast cancer. We evaluated the association between exercise and pathologic complete response (pCR) rate (i.e., ypT0ypN0) in patients receiving neoadjuvant CT for operable breast cancer.
Methods: Using a prospective design, patients with stage I-III breast cancer receiving anthracycline-taxane (± trastuzumab) neoadjuvant CT participating in a multicenter, national cohort study in France (CANTO, NCT01993498) completed questionnaire assessing self-reported exercise behavior (GPAQ 16). Multivariate logistic models were performed to determine the relationship between pre-CT exercise exposure (total MET-h/wk categorized into the proportion of patients meeting WHO exercise guidelines, the equivalent of ≥10 MET-h/wk), pCR rates, CT± trastuzumab dose reductions, delays, treatment completion or interruptions for the overall cohort and on the basis of clinical subtype.
Results: Between March, 2012 to December, 2014, a total of 989 patients participating in CANTO received neoadjuvant CT and completed GPAQ 16. Here we present interim analyses on 608 patients. Fifty-four percent of patients engaged on of ≥10 MET-h/wk prior to CT administration. In multivariable analysis for the overall cohort, exercise exposure was not associated with higher pCR (p=0.69). The pCR rate was 27.7% for patients reporting <10 MET h/wkcompared with 28.0% for those reporting ≥ 10 MET-h/wk (OR, 1.02; 95% CI, 0.71-1.45). Stratification analyses indicated no differences on the basis of clinical subtype for hormone receptor (HR) positive/HER2 negative (<10 MET h/wk: 15.1% vs. ≥ 10 MET h/wk: 16.5%; OR, 0.95, 0.41-2.16); HER2 positive (<10 MET h/wk: 38.1% vs. ≥ 10 MET h/wk: 32.5%; OR, 0.62, 0.28-1.35); or triple-negative disease (<10 MET h/wk: 33.3% vs. ≥ 10 MET h/wk: 36.7%; OR, 1.04, 0.52-2.10). Rates of CT dose reductions (<10 MET h/wk: 16.1% vs. ≥ 10 MET h/wk: 18.3%), CT dose delays (<10 MET h/wk: 19.9% vs. ≥ 10 MET h/wk: 19.8%), CT completion (<10 MET h/wk: 12.03% vs. ≥ 10 MET h/wk: 11.45%) trastuzumab interruptions (<10 MET h/wk: 9.01% vs. ≥ 10 MET h/wk: 7.95%) were also not different on the basis of exercise exposure.
Conclusion: On the basis of interim analyses, higher pretreatment exercise exposure is not associated with higher clinical response or treatment tolerability in breast cancer patients receiving uniform conventional neoadjuvant CT. Full results will be presented at the meeting.
Citation Format: Baker JL, Di Meglio A, El Mouhebb M, Iyengar NM, Michiels S, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Jouannaud C, Levy C, Everhard S, Martin A-L, Arveux P, Fabrice A, Vaz Luis I, Jones LW. Association between exercise, pathological complete response, and treatment tolerability in patients receiving neoadjuvant chemotherapy for operable breast cancer: Results from the CANTO study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-15-03.
Collapse
Affiliation(s)
- JL Baker
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - A Di Meglio
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - M El Mouhebb
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - NM Iyengar
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - S Michiels
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - P Cottu
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - F Lerebours
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - C Coutant
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - A Lesur
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - O Tredan
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - P Soulie
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - L Vanlemmens
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - C Jouannaud
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - C Levy
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - S Everhard
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - A-L Martin
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - P Arveux
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - A Fabrice
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - I Vaz Luis
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| | - LW Jones
- Memorial Sloan Kettering Cancer Center, New York City, NY; Institut Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; Institut Curie Saint Cloud, Saint Cloud, France; Centre Georges-Francois Leclerc, Dijon, France; Insitut de Cancerlogie de Lorraine, Nancy, France; Centre Leon Berard, Lyon, France; Centre Paul Papin, Angers, France; Centre Oscar Lambret, Lille, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre François Baclesse, Caen, France; UNICANCER, Paris, France
| |
Collapse
|
23
|
Vincent-Salomon A, Mathieu MC, Bataillon G, Arnould L, Verrièle V, Ghnassia JP, Haudebourg J, Penault-Llorca F, Lefebvre C, Maran-Gonzalez A, Guinebretière JM, Duprez R, Berghian A, Blanc-Fournier C, Calès V, Galant C, Delrée P, Lemonnier J, Delaloge S, Cottu PH. Abstract P4-15-02: TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The role of chemotherapy in early luminal breast cancer remains challenged. The NEOPAL trial (NCT 02400567; Cottu et al, ESMO 2017 LBA09) compared sequential chemotherapy (CT) and letrozole-palbociclib (LP) as neoadjuvant treatment in PAM50 defined high-risk luminal breast cancer patients, showing that LP might be as efficient as CT with regard to breast conserving surgery and pathological response. We report here extended exploratory pathological results, focusing on tumor infiltrating lymphocytes (TILs), proliferative response and preoperative endocrine prognostic index (PEPI) scores.
Material and Methods
Tumor blocks from baseline biopsy and surgical specimens were available for centralized review from the 106 randomized patients (53 in each arm). TILs quantification, KI67 staining and counting, and ER quantification were performed according to standard methods. Residual proliferative cancer burden (RPCB) and PEPI scores were computed according to published algorithms. Wilcoxon rank sum test and Mann Whitney test were used to compare paired and unpaired data. The chi-square and Fisher exact tests were used for categorical variables.
Results
Overall, median TILs count did not differ between LP and CT patients, both at baseline (p=0.37) and at the end of treatment (p=0.42). Median TILs count climbed from 5% (0-60) to 10% (1-60) in the LP arm (p=0.0026) and from 2% (0-30) to 10% (0-60) in the CT arm (p=0.0023). Median Ki67 dropped sharply in both arms, from 30% (1-80) to 1% (0-30) in the LP arm (p=1.10e-8) and from 30% (2-80) to 5% (0-30) in the CT arm (p=3.10e-9). Decrease in the Ki67 geometric mean was as sharp. Of note, while baseline Ki67 was similar in both arms (p=0.315), decrease in the LP arm was significantly more profound than in the CT arm (p=0.00075). Pathological response according to RPCB were as follows, in the LP and CT arm, respectively: class 0: 9.6%/10.2%; class I: 84.6%/73.5%; class II: 5.8%/16.3%. The relapse free survival PEPI scores were as follow in the LP and CT arm, respectively: class I: 13.5%/16.3%; class II: 59.6%/46.9%; class III: 28.9%/36.8% (p=0.504). Breast cancer specific survival PEPI scores were as follow in the LP and CT arm, respectively: class I: 18.9%/8.2%; class II: 54.7%/40.8%; class III: 26.4%/51%. These results were significantly better in the LP arm (p=0.027). There was no correlation between final TILs quantification and the RPCB or PEPI scores.
Conclusions
In this prospective multicenter study with centralized pathological review, neoadjuvant letrozole-palbociclib combination generates impressive proliferative and endocrine specific response features. It compared well with chemotherapy. The LP combination also significantly increased lymphocytic infiltration. Its clinical significance and utility remain to be elucidated, but it potentially adds new prognostic and theranostic information.
Citation Format: Vincent-Salomon A, Mathieu M-C, Bataillon G, Arnould L, Verrièle V, Ghnassia J-P, Haudebourg J, Penault-Llorca F, Lefebvre C, Maran-Gonzalez A, Guinebretière J-M, Duprez R, Berghian A, Blanc-Fournier C, Calès V, Galant C, Delrée P, Lemonnier J, Delaloge S, Cottu PH. TILs variations, proliferative response and PEPI scores in patients with luminal breast cancer receiving neoadjuvant letrozole-palbociclib or chemotherapy: An extended analysis of the NEOPAL trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-15-02.
Collapse
Affiliation(s)
- A Vincent-Salomon
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - M-C Mathieu
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - G Bataillon
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - L Arnould
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - V Verrièle
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - J-P Ghnassia
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - J Haudebourg
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - F Penault-Llorca
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - C Lefebvre
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - A Maran-Gonzalez
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - J-M Guinebretière
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - R Duprez
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - A Berghian
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - C Blanc-Fournier
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - V Calès
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - C Galant
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - P Delrée
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - J Lemonnier
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - S Delaloge
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| | - PH Cottu
- Institut Curie, Paris, France; PSL Research University, Paris, France; Gustave Roussy, Villejuif, France; Centre George François Leclerc, Dijon, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Paul Strauss, Strasbourg, France; Centre Antoine Lacassagne, Nice, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Sainte Catherine, Avignon, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Curie, Saint-Cloud, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Centre Henri Becquerel, Rouen, France; Centre François Baclesse, Caen, France; Centre Hospitalier de Pau, Pau, France; Cliniques Universitaires Saint-Luc, Bruxelles, Belgium; Unicancer R&D, Kremlin Bicêtre, France; Institut de Pathologie et de Génétique, Charleroi, Belgium
| |
Collapse
|
24
|
Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol 2018; 28:2233-2240. [PMID: 28911063 DOI: 10.1093/annonc/mdx309] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background The role of tumor-infiltrating lymphocytes (TILs) in breast cancer has been extensively studied over the last decade. High TILs levels have been associated with pathological response rate in the neoadjuvant setting and with better outcomes in the adjuvant setting. However, little attention has been paid to changes in TILs and residual TIL levels after neoadjuvant chemotherapy (NAC). We investigated TIL levels before, after chemotherapy, and their dynamics during treatment; and we assessed the correlation of these levels with response to NAC and prognosis. Materials and methods We identified 175 patients with primary HER2-positive breast cancers receiving NAC+/- trastuzumab between 2002 and 2011. Microbiopsy specimens and paired surgical samples were evaluated for stromal lymphocyte infiltration. Univariate and multivariate analyses were carried out to assess the association of clinical and pathological factors with pathological complete response (pCR) and disease-free survival. Results Baseline TIL levels were not significantly associated with pCR. TIL levels decreased during treatment in 78% of the patients. The magnitude of the decrease was strongly associated with pCR. After chemotherapy, TIL levels were high in tumors displaying aggressive patterns (high residual cancer burden score, mitotic index >22, tumor cellularity >5%). In the population with residual disease, TIL levels >25% at the end of NAC were significantly associated with an adverse outcome (TILs >25%, HR = 7.98, P = 0.009) after multivariate analyses including BMI, post-NAC mitotic index and tumor grade. Conclusion A decrease in TIL levels during chemotherapy was positively associated with response to treatment. In tumor failing to achieve pCR, post-NAC lymphocytic infiltration was associated with higher residual tumor burden and adverse clinical outcome. Further studies are required to characterize immune infiltration in residual disease to identify candidates who could benefit from second-line therapy trials including immune checkpoint inhibitors.
Collapse
Affiliation(s)
- A-S Hamy
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris
| | - J-Y Pierga
- Department of Medical Oncology, Institut Curie, Paris.,Faculty of Medicine, Paris Descartes University, Paris
| | - A Sabaila
- Departments of Surgery, Institut Curie, Paris
| | - E Laas
- Departments of Surgery, Institut Curie, Paris
| | - H Bonsang-Kitzis
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris.,Departments of Surgery, Institut Curie, Paris
| | - C Laurent
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris
| | | | - P Cottu
- Department of Medical Oncology, Institut Curie, Paris
| | - F Lerebours
- Department of Medical Oncology, Institut Curie, Paris
| | - R Rouzier
- Departments of Surgery, Institut Curie, Paris.,Equipe d'Accueil 7285, Risk and Safety in Clinical Medicine for Women and Perinatal Health, University Versailles-Saint-Quentin, 2 av de la source de la Biévre, 78180 Montigny-le-Bretonneux, France
| | - M Lae
- Department of Pathology, Institut Curie, Paris, France
| | - F Reyal
- Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, PSL Research University, Institut Curie, Paris.,INSERM, U932 Immunity and Cancer, Paris.,Departments of Surgery, Institut Curie, Paris
| |
Collapse
|
25
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, de la Lande B, Baumann P, Missohou F, Lévy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Pernin V, Kirova Y. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiother 2018; 22:222-228. [PMID: 29650388 DOI: 10.1016/j.canrad.2017.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Accepted: 10/04/2017] [Indexed: 10/17/2022]
Abstract
PURPOSE To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. MATERIAL AND METHODS This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion. The study was designed to evaluate the toxicity at one year, 3 years and 5 years. RESULTS Sixty-four patients were included from October 2007 to August 2010. All of them received concurrent adjuvant radiotherapy and bevacizumab (in 24 cases after primary systemic treatment). All patients received non-fractionated radiotherapy to breast or chest wall with or without irradiation of regional lymph nodes. Early toxicity has been previously reported. Median follow-up was 46.4 months (range: 18-77 months). Median age was 53 years old (range: 23-68 years). The 3-years overall survival was 93% (range: 87-100%). Evaluation of the toxicity at 3 years was available for 67% of the patients. There was a low rate of toxicity: 14% grade 1 pain, 9% grade 1 fibrosis, 2% grade 1 telangiectasia, 2% grade 1 paresis, 7% grade 1 lymphedema and 2% grade 3 lymphedema. No grade 4 toxicity was observed. No patient had a left ventricular ejection fraction below 50% at 3 years. CONCLUSIONS Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.
Collapse
Affiliation(s)
- A Dautruche
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
| | - L Belin
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Cottu
- Oncology department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - P Bontemps
- Radiotherapy department, CHU Jean-Minjoz, 25030 Besançon, France
| | - C Lemanski
- Radiotherapy department, institut régional du cancer de Montpellier, 34298 Montpellier, France
| | - B de la Lande
- Radiotherapy department, institut Curie, René-Huguenin hospital, 92210 Saint-Cloud, France
| | - P Baumann
- Radiotherapy department, centre d'oncologie de Gentilly, 54000 Nancy, France
| | - F Missohou
- Radiotherapy department, centre Henri-Becquerel, 76038 Rouen, France
| | - C Lévy
- Radiotherapy department, centre François-Baclesse, 14000 Caen, France
| | - K Peignaux
- Radiotherapy department, centre Georges-François-Leclerc, 21079 Dijon, France
| | | | - F Denis
- Radiotherapy department, centre Jean-Bernard, 72000 Le Mans, France
| | - A Gobillion
- Biostatistics department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - V Pernin
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| | - Y Kirova
- Radiotherapy department, institut Curie, 26, rue d'Ulm, 75005 Paris, France
| |
Collapse
|
26
|
Chamorey E, Ferrero J, Cottu P, Brain E, Bachelot T, Debled M, Schiappa R, Campone M, Goncalves A, Levy C, Mailliez A, Veyret C, Petit T, Uwer L, Jacot W, Dalenc F, Mouret-Reynier M, Hennequin A, Simon G, Delaloge S. Outcomes of 9800 metastatic luminal HER2-negative breast cancer patients in the French national real-life UNICANCER ESME-breast cohort. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30286-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
27
|
Cottu PH, Amar Y, Pistilli B, Bonsang-Kitzis H, Lesur A, Lerebours F, Vanlemmens L, Tredan O, Levy C, Jouannaud C, Fournier M, Soulie P, Rigal O, Giacchetti S, Arnaud A, Arsene O, Savignoni A, Mesleard C, Andre F, Arveux P. Abstract P6-12-18: CANTOCHEM: Analysis of chemotherapy practice and early side effects in the 6090 first patients from the prospective CANTO cohort. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-12-18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
There is no large prospective trial assessing mid-term adverse effects of adjuvant chemotherapy. In order to address this question, we developed CANTO (CANcer TOxicities - NCT01993498 - http://etudecanto.org/), a prospective trial dedicated to the quantification of side effects after treatment for patients with early breast cancer and to develop predictors of such toxicities. The aim of this presentation is to assess chemotherapy (CT) practice and to report toxicities that persist 3-6 months after CT.
Methods
CANTO is a prospective study enrolling newly diagnosed invasive cT0-cT3, cN0-3, M0 breast cancer patients (pts) of 26 French comprehensive cancer centers. The study has included 10 500 patients at the time of submission. Pts are assessed at diagnosis, 3-6, 12, 36, 48 and 60 months after treatment completion. CANTO collects >100 items related to toxicities. In the current study, we focus on the first set of data available from the trial (1st database lock, n=6090). We here assess CT practice and toxicities at 3 months.
Results
Information about (neo)adjuvant CT (NACT/ACT) is available in 5805 pts (96%). Median age at diagnosis was 57y (22-93). Pts had HR+/HER2-, HER2+ or triple negative (TN) tumors in 74%, 15% and 11% of cases. Ki67 was assessed in 70%, and genomic tests in 1% of pts, respectively.
Overall, 3074 pts (53%) received CT, either adjuvant (ACT: 76%) or neoadjuvant (NACT: 24%). ACT/NACT pts (84%) received a sequential anthracyclines–taxanes based 6 courses CT schedule. CT was administered in 44.7%, 87.2% and 92.3% of HR+/HER2+/TN tumors, respectively. ACT was administered in 73.2% of pT2+ pts (vs 36.0% in pT0-1 – p<.001)) and in 74.7% in pN1+pts (vs 36.7% in pN0 – p<.001)). After NACT, pts had yPT0 (32.3%) and/or ypN0 (64.6%) for an overall 28.9% pCR rate.
We focus here on clinically most relevant patient reported symptoms at 3 m (any grade).
side effects at 3m no CT (%)CT (%)p valuePain76.682.1<.001Neurological symptom4768.7<.001GI symptom34.342.1<.001CV sympton8.110.20.011
Pain complaint was recorded in 3596 pts (97.2% of pts with available data), with a median value of 4 on the VAS (range 1-10). In ACT/NACT pts, muscle and joint pain were predominant. Neurological symptoms were seen in 3024 pts (59%), the most frequent pertaining to cognitive disorder (attention trouble, CT: 61.2% vs noCT: 56% - p=.06) and peripheral neuropathy (overall 31%). Paresthesias and sensory neuropathy were much more frequent in CT vs noCT pts: respectively 37.3% vs 20.3% and 25.7% vs 12.8% (both p<.001). Of note, pts receiving paclitaxel had more peripheral neuropathy (92.3% vs 69% in docetaxel pts – p=.07). Diarrhea was the most frequent GI symptom post CT: 44.5% vs 33.2%, p< 0.001. CV symptoms (NOS) were slightly more frequent after CT.
Conclusions
In this real life, prospective cohort, CT is frequently prescribed and appears in good compliance with current guidelines. Overall, symptoms burden at treatment completion is strikingly high, and much higher in pts receiving CT. A special attention should be given to pain and neurological symptoms. Dedicated questionnaires and sub-studies will explore in depth these side effects. Extended analyses of CT practice and toxicities will be presented.
Citation Format: Cottu PH, Amar Y, Pistilli B, Bonsang-Kitzis H, Lesur A, Lerebours F, Vanlemmens L, Tredan O, Levy C, Jouannaud C, Fournier M, Soulie P, Rigal O, Giacchetti S, Arnaud A, Arsene O, Savignoni A, Mesleard C, Andre F, Arveux P. CANTOCHEM: Analysis of chemotherapy practice and early side effects in the 6090 first patients from the prospective CANTO cohort [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-12-18.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - Y Amar
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - B Pistilli
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - H Bonsang-Kitzis
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Lesur
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - F Lerebours
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - L Vanlemmens
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Tredan
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Levy
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Jouannaud
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - M Fournier
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - P Soulie
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Rigal
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - S Giacchetti
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Arnaud
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - O Arsene
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - A Savignoni
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - C Mesleard
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - F Andre
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| | - P Arveux
- Institut Curie, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France; Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Saint-Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; Centre François Baclesse, Caen, France; Institut Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Henri Becquerel, Rouen, France; CHU Saint-Louis, Paris, France; Institut Sainte Catherine, Avignon, France; CH Blois, Blois, France; R & D Unicancer, Paris, France; Centre Georges François Leclerc, Dijon, France
| |
Collapse
|
28
|
Frank S, Tchokothe C, Carton M, Mouret-Fourme E, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Leheurteur M, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Guesmia T, Bachelot T, Robain M, Cottu P. Abstract P6-08-10: Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-08-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Young age is a known poor prognosis factor in early stage breast cancer (BC). Its value is less documented for metastatic BC (MBC). Guidelines state that age should not guide the treatment strategy. We used the ESME database to evaluate the impact of age at MBC diagnosis on overall survival (OS).
Patients and Methods
ESME is a unique national cohort, collecting retrospective data using clinical trial-like methodology. It included all consecutive MBC patients (pts) who initiated at least 1 treatment in one of the 18 participating French cancer centers between 01/01/2008 and 12/31/2014. The database was locked on 12/8/2016. Primary objective were the comparisons of MBC characteristics between age groups (<40, 40 to 60 and >60 years (y)) and the evaluation of the impact of age at MBC diagnosis on OS.
Interaction between age and tumor subtype was tested using a Cox regression model.
ResultsAmong 16 703 included pts, 1539 had no information on tumor receptors (ER/PR/HER2) and 682 had an exclusion criteria (unknown age, men or other cancer in the last 5y), leaving 14 482 for analysis. At the onset of MBC, 902 pts (6.2%), 6269 (43.3%) and 7311 (50.5%) were <40y, 40y to 60y and older than 60y respectively. Median follow-up was 54.8 months.
Pts <40 had significantly more aggressive presentations than other age groups: more HER2+ (26.5%), and triple negative (26.4%) subtypes, more visceral involvement (57.1%), and shorter time to metastasis (26.9% between 6 to 24 months) (all p-value vs other age groups <0.0001).
MBC characteristics according to age groups Age at MBC diagnosis (years)p-value <4040-60>60 Tumor subtype <0.0001HR+/HER2-425 (47.12)3816 (60.87)5262 (71.97) HR-/HER2-238 (26.39)1126 (17.96)884 (12.09) HER2+239 (26.5)1327 (21.17)1165 (15.93) Type of metastasis, N(%) <0.0001Bone only219 (24.31)1832 (29.23)2367 (32.41) Non visceral168 (18.65)1046 (16.69)1314 (17.99) Visceral514 (57.05)3389 (54.08)3623 (49.6) Time to first metastasis (months), N(%) <0.0001< 6304 (33.74)1882 (30.1)2107 (28.9) [6-12[65 (7.21)241 (3.85)209 (2.9) [12-24[177 (19.64)760 (12.15)564 (7.7) ≥24355 (39.4)3370 (53.89)4416 (60.53) Number of metastatic sites, N(%) 0.51 site709(78.6)4948 (78.93)5805 (79.4) 2 sites163(18.07)1130 (18.03)1313(17.96) ≥3 sites30(3.33)191 (3.05)193 (2.64)
Overall, median OS was identical in the different age groups: 39.1, 41.1 and 39.8 months for pts <40, 40-60 and >60, respectively (p=0.2).
Tumor subtype and age showed a significant interaction on OS (p<0.0001), especially among HER2+ MBC
Overall survival (months) according to tumor subtypes and age groups Age groups (years)p-value (log-rank)Tumor subtype<4040-60>60 HR+/HER2-46,4 (CI 95% 40.5-55.4)47,8 (CI 95% 46-50)44,2 (CI 95% 42.1-46.3)0.0023HER2+60,7 (CI 95% 45.6-76.4)50,4 (CI 95% 46.3-56.3)44 (CI 95% 38.8-48.9)<0.0001Triple negative14 (CI 95% 11.5-16.5)14,7 (CI 95% 13.7-15.9)15,7 (CI 95% 14.6-17.1)0.01
. Anti-HER2 with first-line treatment was given preferentially to young pts: 86.6, 81.9 and 74.9%for pts <40, 40-60 and >60, respectively (p<0.0001).
Conclusion
At onset of MBC, young age was associated with more aggressive presentations, however with no global impact on OS. Pts <40 with HER2+ disease carried a better prognosis, maybe related to therapy.
Citation Format: Frank S, Tchokothe C, Carton M, Mouret-Fourme E, Dubot C, Campone M, Pistilli B, Dalenc F, Mailliez A, Levy C, D'Hondt V, Debled M, Leheurteur M, Coudert B, Perrin C, Gonçalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Guesmia T, Bachelot T, Robain M, Cottu P. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life "ESME" cohort [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-08-10.
Collapse
Affiliation(s)
- S Frank
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - C Tchokothe
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M Carton
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - E Mouret-Fourme
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - C Dubot
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M Campone
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - B Pistilli
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - F Dalenc
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - A Mailliez
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - C Levy
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - V D'Hondt
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M Debled
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M Leheurteur
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - B Coudert
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - C Perrin
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - A Gonçalves
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - L Uwer
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - J-M Ferrero
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - J-C Eymard
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - T Petit
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M-A Mouret-Reynier
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - T Guesmia
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - T Bachelot
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - M Robain
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| | - P Cottu
- Institut Curie, Paris/Saint Cloud, France; Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France; Gustave Roussy, Villejuif, France; Institut Claudius Régaud, Toulouse, France; Centre Oscar Lambret, Lille, France; Centre François Baclesse, Caen, France; Institut du Cancer de Montpellier, Montpellier, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean Perrin, Clermont-Ferrand, France; R&D Unicancer, France; Centre Léon Bérard, Lyon, France
| |
Collapse
|
29
|
Pistilli B, Filleron T, Mazouni C, Zingarello A, Lacroix-Triki M, Rivera S, Coudert B, Serin D, Canon JL, Campone M, Bachelot T, Goncalves A, Levy C, Cottu P, Petit T, Eymard JC, Tunon De Lara C, Roché H, Roca L, Lemonnier J, Delaloge S. Abstract P1-07-07: Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-07-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:Incidence of LRs in patients (pts) treated for HR+ HER2- localized BC and distribution overtime have not been described in recent years after introduction of new generation of adjuvant therapies and more extensive use of radiotherapy. We evaluated the incidence and distribution overtime of LRs in pts with HR+ HER2- N+ BCs who entered PACS 01 and PACS04 trials.
Patients and Methods: Data were analyzed from 2909 pts with HR+/HER2- BC out of 5008 included in both trials. Pts underwent mastectomy or lumpectomy plus axillary dissection for a localized N+ BC and, according to study design, were randomized to: 6 cycles of FE100C (standard arm) versus FE100C x 3 cycles followed by docetaxel 100 mg/m2 x 3 cycles (FEC-D) (PACS01) or 6 cycles of Epirubicin 75mg/m2 and Docetaxel 75 mg/m2 (ED75)(PACS04). Loco-regional radiotherapy was mandatory after lumpectomy and recommended in other cases. All pts received 5 years of hormone therapy (HT). A competing risk multivariate analysis was conduct using Fine and Gray model to identify risk factors associated to isolated LRs. Competing events were nodal recurrence, contralateral BC, distant metastasis and death. Cumulative incidence associated to each event was estimated by a Kablfleish-Prentice estimator.
Results: Pts' median age was 50 (22-65); 67.2% underwent lumpectomy, 32.8% mastectomy; 67.6% had 1 to 3 N+, 32.4% more than 3 N+; 45.7% had lymphovascular invasion; 49.5% received FE100C, 35.8% ET75, 14.7% had FEC-D; while radiotherapy was given to 97.3% and HT to 92.2%, of whom 90.5% received tamoxifen. At a median follow-up of 9.1 years, 60 pts (2.1%) experienced LR as first event. The 5-year and 10-year cumulative incidence of LRs were 1.04% and 2.53%, respectively. The cumulative incidence of LRs increased from the 5th year, and the annual risk tended to remain constant over time. Multivariate analysis of competing risk showed that younger age, conservative surgery and omission of HT (not prescribed or non-adherence) were independently associated with risk of developing LRs.
Table 1. Multivariate analysis on competing risk of predictors of LRsVariablesHR 95%CIP valueAge at entry (<35 years, ≥ 35)*0.95 [0.92; 0.99]0.009Mastectomy, lumpectomy0.39 [0.17; 0.86]0.020> 20mm, ≤20 mm0.68 [0.37; 1.24]0.203N+ >3, 1-31.73 [0.99; 3.02]0.055Grade II/III, I1.06 [0.50; 2.24]0.885PR+,PR-1.78 [0.70; 4.53]0.223Type of chemotherapy 3FEC-3D, 6FEC/6ET1.32 [0.65; 2.69]0.446Number of cycles 6, <60.71 [0.17; 0.75]0.630Hormone therapy Yes,No0.36 [0.17; 0.75]0.006*treated as continuous variable
Conclusion: Our analysis showed that incidence of LRs in pts with HR+ N+ BCs treated within PACS trials were considerably lower as compared to earlier studies. These findings may reflect differences in treatment era, as the more extensive use of radiotherapy and new generation of adjuvant chemotherapy. Despite current adjuvant strategies, young age at diagnosis and omission of HT remain independent risk factors of LRs.
Citation Format: Pistilli B, Filleron T, Mazouni C, Zingarello A, Lacroix-Triki M, Rivera S, Coudert B, Serin D, Canon J-L, Campone M, Bachelot T, Goncalves A, Levy C, Cottu P, Petit T, Eymard J-C, Tunon De Lara C, Roché H, Roca L, Lemonnier J, Delaloge S. Overtime distribution and predictors of local recurrences (LRs) in patients with hormone receptor positive (HR+) and node positive (N+) breast cancers (BCs): 10 -year follow-up analysis of UNICANCER-PACS 01 and PACS04 trials [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-07-07.
Collapse
Affiliation(s)
- B Pistilli
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - T Filleron
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - C Mazouni
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - A Zingarello
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - M Lacroix-Triki
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - S Rivera
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - B Coudert
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - D Serin
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - J-L Canon
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - M Campone
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - T Bachelot
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - A Goncalves
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - C Levy
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - P Cottu
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - T Petit
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - J-C Eymard
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - C Tunon De Lara
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - H Roché
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - L Roca
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - J Lemonnier
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| | - S Delaloge
- Institut Gustave Roussy, Villejuif, France; Biostatistics Unit, Institut Claudius Regaud Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; IRCCS AOU San Martino - IST, Genova, Italy; Centre Georges François Leclerc, Dijon, France; Institut Sainte Catherine, Avignon, France; Grand Hopital de Charleroi, Charleroi, France; Institut de Cancérologie de l'Ouest, Angers, France; Centre Léon Bérard, Lyon, France; Institut Paoli Calmettes, Marseille; Centre François Baclesse Avenue Général Harris, Caen, France; Institut Curie, Paris, France; Centre Paul Strauss, Strasbourg, France; Institut de Cancérologie Jean Godinot, Reims, France; Institut Bergonié, Bordeaux, France; Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; UNICANCER, Paris, France
| |
Collapse
|
30
|
Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, Mailliez A. Abstract P6-14-02: Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-14-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In 2014, UNICANCER (composed of 18 French Comprehensive Cancer Centers) launched the Epidemiological Strategy and Medical Economics (ESME) program to investigate real-world data in solid tumors. Real-world data give the opportunity to assess for the activity of specific drugs outside clinical trials. Eribulin is approved for pre-treated metastatic breast cancer (MBC). Marketing authorization has been granted in France in July 2012. However few data are available regarding its efficacy in real life. We evaluated eribulin use as second and third line of chemotherapy in MBC patients from the ESME database.
Methods: Data from all newly diagnosed MBC patients having initiated at least one treatment between Jan. 2008 and Dec. 2014 are included in the ESME database. Data were collected retrospectively using a clinical trial-like methodology. Primary endpoint was overall survival (OS), defined from the starting date of second or third line chemotherapy (eribulin versus other chemotherapy). Progression-free survival (PFS) was calculated as a secondary endpoint.
Results: Of 16,703 MBC patients included in the ESME database, 7,412 received at least 2 lines of chemotherapy: eribulin/other chemotherapy, total 1,966/5,446, second line 363/5,446, third line 654/2,669. Depending on second or third line chemotherapy use classification, median age was 59 years (range 20-97) and 58 year (range 21 – 94), triple negative tumors accounted for 20% and 19% of cases, and median follow-up reached 26 months and 22 months respectively.
Table reports median OS and PFS, according to lines and type of chemotherapy.
OS eribulin (months)OS other chemotherapy (months)pPFS Eribulin (months)PFS other chemotherapy (months)pSecond line12.4 (11.3-15.1)11.8 (11.3-12.3)0.4654.1 (3.7-4.9)4.1 (4.0-4.3)0.9225Third line10.3 (9.3-11.5)7.7 (7.3-8.0)<.00013.6 (3.2-3.9)3.0 (2.9-3.2)0.0058
Supportive analyses (using a propensity score for adjustment and as a matching factor for nested case–control analyses) and sensitivity analyses will be available for full presentation at the meeting.
Conclusion: In this large-scale real-life setting, MBC patients treated with third line eribulin showed an improved OS and PFS compared with those receiving another chemotherapy. The difference was not statistically significant for second line treatment.
Citation Format: Jacot W, Heudel P-E, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero J-M, Eymard J-C, Petit T, Mouret-Reynier M-A, Courtinard C, Cottu P, Robain M, Mailliez A. Real-life activity of eribulin among metastatic breast cancer patients in the multicenter national observational ESME program [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-14-02.
Collapse
Affiliation(s)
- W Jacot
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - P-E Heudel
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - J Fraisse
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Gourgou
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Guiu
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - F Dalenc
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - B Pistilli
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Campone
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Levy
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Debled
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Leheurteur
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Chaix
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Lefeuvre
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Goncalves
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - L Uwer
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - J-M Ferrero
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - J-C Eymard
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - T Petit
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M-A Mouret-Reynier
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Courtinard
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - P Cottu
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Robain
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Mailliez
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France; Centre Léon Bérard, Lyon, France; IUCT Oncopole, Toulouse, France; Gustave Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Centre François-Baclesse, Caen, France; Institut Bergonié, Bordeaux, France; Centre Henri Becquerel, Rouen, France; Centre Georges Francois Leclerc, Dijon, France; Centre Eugène Marquis, Rennes, France; Institut Paoli-Calmettes, Marseille, France; Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie Jean Godinot, Reims, France; Centre Paul Strauss, Strasbourg, France; Centre Jean-Perrin, Clermont-Ferrand, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
31
|
Cottu PH, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel P, Duhouix F, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Vincent-Salomon A, Lemonnier J, Delaloge S. Abstract P3-13-02: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-13-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - V D'Hondt
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - S Dureau
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - F Lerebours
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - I Desmoulins
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - P Heudel
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - F Duhouix
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - C Levy
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - M-A Mouret-Reynier
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - F Dalenc
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - J-S Frenel
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - C Jouannaud
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - L Venat-Bouvet
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - S Nguyen
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - J-M Ferrero
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - J-L Canon
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - J Grenier
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - J Lemonnier
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| | - S Delaloge
- Institut Curie, Paris, France; Institut de Cancérologie de Montpellier, Montpellier, France; Centre Gerorges François Leclerc, Dijon, France; Centre Léon Bérard, Lyon, France; Cliniques Saint-Luc, Louvain, Belgium; Centre Fraçois Baclesse, Caen, France; Centre Jean Perrin, Clermont Ferrand, France; Institut Universitaire de Cancérologie de Toulouse, Toulouse, France; Institut de Cancérologie de l'Ouest, Saint-Herblin - Angers, France; Centre Henri Becquerel, Rouen, France; Limoges University Hospital, Limoges, France; Pau Hospital, Pau, France; Centre Antoine Lacassagne, Nice, France; Grand Hôpital de Charleroi, Charleroi, Belgium; Institut Sainte Catherine, Avignon, France; R & D Unicancer, UCBG, Paris, France; Gustave Roussy Cancer Campus, Villejuif, France
| |
Collapse
|
32
|
Zamagni C, Martin M, Ring A, Cottu P, Zhou K, Wu J, Zarate J, De Laurentiis M. CompLEEment-1: phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, Diéras V, Cabel L, Pierga JY, Bidard FC. Circulating tumor cell count and thrombosis in metastatic breast cancer. J Thromb Haemost 2017; 15:1981-1988. [PMID: 28779538 DOI: 10.1111/jth.13792] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Indexed: 11/28/2022]
Abstract
Essentials Tumor cells circulating in blood (CTC) may favor thrombotic events in cancer patients. We assessed the impact of CTC on the risk of thrombosis in metastatic breast cancer. Baseline CTC detection was the only independent factor associated with the risk of thrombosis. CTC detection under therapy may be the hidden link between tumor progression & thrombosis. SUMMARY Background Circulating tumor cell (CTC) count is a major prognostic factor in metastatic breast cancer (MBC) and has been reported to be associated with thrombosis in short-term studies on MBC patients. Objective To assess whether CTC detection (CellSearch® ) before first-line chemotherapy impacts the risk of thrombosis throughout the course of MBC. Patients/Methods Among patients included before first-line chemotherapy for MBC in the prospective IC2006-04 CTC detection study (NCT00898014), the electronic medical files of those patients treated at Institut Curie (Paris, France) were searched in silico and manually checked for incident venous or arterial thrombotic events (TE) in the course of MBC. Univariate and multivariate analyses were performed using Cox and Fine-Gray models, adjusted for age and Khorana score. Results/Conclusions With a median follow-up of 64 months (25-81 months), among the 142 patients included, 34 (24%) experienced a TE (incidence rate, 8 TE/100 patient-years). The TE incidence rate was 13 TE/100 patient-years for the 80 patients with ≥ 1 CTC/7.5 mL of blood before initiating first-line chemotherapy, vs. only 4 TE/100 patient-years for the 62 CTC-negative patients. Fine-Gray multivariate analysis (with death as competing event) included age, Khorana score and baseline lactate dehydrogenase and CTC levels: detectable CTC was the only factor significantly associated with an increased risk of TE (sub-distribution hazard ratio [SHR] for patients with [1-4] CTC = 3.1, 95% CI [1.1; 8.6], SHR for patients with ≥ 5 CTC = 1.4, 95% CI [0.5; 4.6]). This study shows that CTC detection before starting first-line chemotherapy is an independent risk factor for TE in MBC patients.
Collapse
Affiliation(s)
- G Beinse
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - F Berger
- Institut Curie, Unit of Biometry, PSL Research University, INSERM U900, Paris, France
| | - P Cottu
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - M-E Dujaric
- Institut Curie, Unit of Biometry, PSL Research University, INSERM U900, Paris, France
| | - I Kriegel
- Department of Anesthesiology, Institut Curie, PSL Research University, Paris, France
| | - M-N Guilhaume
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - V Diéras
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - L Cabel
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| | - J-Y Pierga
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
- Université Paris Descartes, Paris, France
| | - F-C Bidard
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France
| |
Collapse
|
34
|
de La Motte Rouge T, Cottu P, Pautier P, Provansal M, Floquet A, Selle F, Fabbro M, Kalbacher E, Follana P, Lesoin A, Medioni J, Dupin J, Ferri RM, Bidard FC, Dubot C, Rouzier R, Joly Lobbedez F. Circulating tumor cells as prognostic marker in ovarian carcinoma: Results from the ANTHALYA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx372.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux F, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Lemonnier J, Vincent-Salomon A, Delaloge S. Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
|
36
|
De Laurentiis M, Martin Jimenez M, Ring A, Cottu P, Zhou K, Wu J, Zarate J, Zamagni C. CompLEEment-1: Phase 3b study of ribociclib + letrozole for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Lardy-Cleaud A, Cottu P, Frank S, Le Saux O, Chabaud S, Parent D, Pistilli B, Debled M, Mailliez A, Veyret C, Petit T, Uwer L, Guiu S, Ung M, Chamorey E, Arveux P, Guesmia T, Augereau P, Simon G, Bachelot T. Use of everolimus in advanced hormone receptor positive metastatic breast cancer in a multicenter national observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Jacquet E, Lardy-Cleaud A, Pistilli B, Cottu P, Delaloge S, Debled M, Vanlemmens L, Anne-Valérie G, Leheurteur M, Laborde L, Jacot W, Berchery D, Coudert B, Ferrero JM, Parent D, Diéras V, Velten M, Courtinard C, Robain M, Bachelot T. Survival of patients with aromatase inhibitors sensitive, HR+/HER2- metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Pistilli B, Lardy-Cleaud A, Jacquet E, Delaloge S, Cottu P, Debled M, Vanlemmens L, Leheurteur M, Divanon F, Gonçalves A, Laurent C, Coudert B, Chamorey E, Campion L, Mouret-Reynier MA, Breton M, Petit T, Simon G, Cailliot C, Bachelot T. FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2- negative metastatic breast cancer patients (MBC) ≤45 years old. A large observational multicenter cohort survival analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study. Eur J Cancer 2017. [PMID: 28648618 DOI: 10.1016/j.ejca.2017.05.009] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
HannaH (NCT00950300) and PrefHer (NCT01401166) studies validated the subcutaneous (H-s.c.) formulation of trastuzumab as effective and safe as intravenous (H-i.v.) and highly preferred by patients in early breast cancer. The present randomised MetaspHer trial (NCT01810393) is the first study assessing patient's preference in metastatic setting. METHODS Patients with HER2-positive metastatic breast cancer who completed a first line chemotherapy with trastuzumab and achieved a long-term response lasting more than 3 years were randomised to receive 3 cycles of 600-mg fixed-dose adjuvant H-s.c., followed by 3 cycles of standard H-i.v., or the reverse sequence. Primary end-point was overall preference for H-s.c. or H-i.v. at cycle six, assessed by Patient Preference Questionnaire (PPQ). Secondary end-points included healthcare professional (HCP) satisfaction; safety and tolerability; quality of life. RESULTS Hundred and thirteen patients were randomised and treated. H-s.c. was preferred by 79/92 evaluable intent-to-treat patients (85.9%, 95% confidence interval [CI; 78.8-93.0]; p < 0.001), 13/92 preferred H-i.v. (14.1%, 95% CI [7.0-21.3]). HCPs were most satisfied with H-s.c. (56/88 available data, 63.6%, [53.6-73.7]). On the safety population, adverse events occurred in 73 (67.6%) and 49 (44.1%) patients during the H-s.c. and H-i.v. periods, respectively; 7 (6.5%) and 4 (3.6%) were grade ≥ III, 3 (2.8%) and 2 (1.8%) were serious. CONCLUSION The safety was consistent with the known H-i.v. and H-s.c. profiles without safety concern raised. Definitively, patients preferred H-s.c. as reported in early stage by PrefHer study.
Collapse
Affiliation(s)
- X Pivot
- University Hospital Jean Minjoz, INSERM 1098, Besancon, France.
| | - J P Spano
- AP-HP Pitié-Salpêtrière-Charles Foix, UPMC Université Paris 06, Paris, France
| | - M Espie
- Hôpital Saint Louis, AP-HP, Paris, France
| | - P Cottu
- Institut Curie, Paris, France
| | | | - V Pottier
- Centre Leonard De Vinci, Dechy, France
| | - L Moreau
- Pôle Santé République - Clinique Clermont-Ferrand, Clermont Ferrand, France
| | - J M Extra
- Institut Paoli-Calmettes, Marseille, France
| | | | - P Rivera
- Institut Claudius-Regaud, Toulouse, France
| | - D Spaeth
- Gentilly Oncology Centre, Nancy, France
| | | | | | | | | | - J Gligorov
- APHP Tenon, Inserm U938, IUC-UPMC Sorbonne Université, Paris, France
| |
Collapse
|
41
|
Rouzier R, Bonneau C, Cayre A, Hequet D, Gentien D, Bonhomme A, Mouret-Reynier MA, Dubot C, Cottu P, Roulot A, Morel P, Salomon A, Callens C, Guinebretiere JM, Penault-Llorca F. Abstract P2-05-04: Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-04] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recent molecular biology technologies reveals insight into tumor heterogeneity but quantification and impact on reproducibility of tests is not well known. The objective of this study was to assess the extent to which tumor heterogeneity may affect the prognosis of patients assessed by Prosigna™ (PAM50) gene signature assay compared to test reproducibility.
Methods: Reproducibility was measured by testing replicate tissue sections from 186 FFPE breast tumor blocks across 2 sites (Institut Curie, Centre Jean Perrin) following independent pathology review at each site. Consecutive slides came from blocks of patients included in the Decision Impact prospective study which examined whether the Prosigna™ test influences adjuvant treatment decision (Clinical trial information: NCT02395575). To evaluate heterogeneity and its impact in terms of outcome, we selected among T1N0 patients treated in Institut Curie between 2003 and 2008, 32 patients who did recur and 28 matched control group who did not (2 'controls' recurred during the study). Analyses were performed on two parts of each tumor. NanoString's Prosigna™ outputs (risk of recurrence (ROR) score, 10 year probability of distant recurrence, risk category, and intrinsic subtype (Luminal A/B, HER2-enriched, Basal-like)) were measured and compared to evaluate heterogeneity (defined as difference in terms of subtype and/or risk category between the two parts) and reproducibility. Correlation between heterogeneity and outcome was performed. Impact was assessed by tumor board analysis.
Results: Pearson correlation coefficients for ROR score and probability of distant recurrence predicted were .95 and .97, respectively in the reproducibility study and .82 and .86, in the tumor heterogeneity study. The measured standard deviation (SD) was 5.4 and 8.1 ROR units corresponding to 1.6% and 2.8% in terms of risk of distant metastasis free survival within the reproducibility study and the tumor heterogeneity study, respectively. Kappa coefficients for intrinsic subtype and risk category agreement were 0.88 and 0.87 in the reproducibility study, and 0.67 and 0.58 in the tumor heterogeneity study. Tumor board analysis of discordant cases showed that the impact, in terms of decision of chemotherapy administration, concerns 3% of patients because of reproducibility and 8% because of tumor heterogeneity, comparing favorably with the discordance between Prosigna™ and immunohistochemistry (27%). Probability of distant recurrence was higher in the cases (15%) compared to control (9%) (p=.001) in the tumor heterogeneity study confirming the performance of the Prosigna™ test.
Conclusion: We validated in the prospective Decision Impact study the analytical performance of NanoString's Prosigna™ assay across multiple clinical testing laboratories. We showed in these two studies that tumor heterogeneity has more impact than reproducibility performance. The clinical impact on the decision making based on tumor heterogeneity is however limited, since it does not correlate to outcomes, whereas the Prosigna™ ROR score has been shown to correlate very well to outcomes.
Citation Format: Rouzier R, Bonneau C, Cayre A, Hequet D, Gentien D, Bonhomme A, Mouret-Reynier M-A, Dubot C, Cottu P, Roulot A, Morel P, Salomon A, Callens C, Guinebretiere J-M, Penault-Llorca F. Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-04.
Collapse
Affiliation(s)
- R Rouzier
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - C Bonneau
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - A Cayre
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - D Hequet
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - D Gentien
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - A Bonhomme
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - M-A Mouret-Reynier
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - C Dubot
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - P Cottu
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - A Roulot
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - P Morel
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - A Salomon
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - C Callens
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - J-M Guinebretiere
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| | - F Penault-Llorca
- Institut Curie, Saint-Cloud, France; Centre Jean Perrin, Clermont Ferrand, France; Nanostring
| |
Collapse
|
42
|
Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard FC, Servois V, Comte A, Belin L, Sigal B, Bièche I. Abstract PD1-06: Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-pd1-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Genomic profile of breast cancer metastases (M) may differ from that of the primary tumor (PT). In a multicenter prospective study (ESOPE, NCT 01956552) including 130 patients with biopsies of the first metastatic deposit, we have shown that luminal breast cancers are the most prone to phenotypical subtype changes (Comte et al, ASCO 2016#550). We report here the first results of a comparative PT/M targeted next generation sequencing (NGS) mutational analysis.
Methods
Of 130 patients, 117 paired PT/M samples obtained before any treatment were available for analysis. Targeted Sequencing was done using Illumina Hiseq2500 technology with a custom made 95 breast cancer associated genes panel. Sequence data were aligned to the human reference genome (hg19) using Bowtie2 algorithm. Median depth was 607X and 87% of targets achieved 100X depth. SNVs and indels were called using GATK UnifiedGenotyper. We retained COSMIC confirmed non synonymous, exonic/splice variants and observed at a frequency lower than 0,1% in population. Further confirmation of detected variants was performed with comparison to public databases (cbioportal, tumorportal), and potential pathogenicity was evaluated with 4 different public algorithms. We present here the results obtained from the first 35 matched PT/M samples (liver mets 68%), focusing analysis on 40 genes including PIK3CA (20 genes), ER (6 genes) and MAPK (11 genes) pathways, RUNX1, CDH1 and TP53 genes.
Results
Patients characteristics are representative of patients with first line metastatic breast cancer (Comte et al, ASCO 2016#550). Among the 40 genes analyzed in the 70 samples, we detected 134 somatic mutations (70 in PT and 64 in M) including 15 indels and 119 SNV. Among these 134 mutations there were 74 different mutations (66SNV and 8 indels) classified pathogenic for 26 and of unknown pathogenicity for 48 of them. We detected at least 1 mutation in 31 PT and in 28 M. Median numbers of mutations were 1 in PT (range 1-9) and 1 in M (range1-22) samples (p=0.295, Wilcoxon rank sum test). Top ten mutated genes in PT included PIK3CA, TP53, NCOR1, NF1, GATA3, CDH1, ERBB3, PTEN, HRAS, INPP4B. In M samples, the 10 top genes were PIK3CA, TP53, ERBB3, AKT3, CDH1, ERBB4, GATA3, INPP4B, MET, MTOR. Only 3 ESR1 mutations were detected, including 1 PT/M pair and 1 M. Beyond highly shared PIK3CA and TP53 mutations, overall crude PT/M discordance rate was 31%. Analysis by histological subtypes showed PT and M specific mutational profiles, suggesting a role in ERB gene family (notably ERBB3) and MAPK driven pathways in early metastatic progression. Specific metastatic site analysis suggested enrichment in MAPK pathway mutations in liver metastases when compared to other sites. Variant allelic fractions were globally not significantly different between PT and M samples.
Conclusion
In this prospective multicenter series of systematic biopsies of first metastases, we report a targeted mutational analysis of matched PT and M samples not modified by previous therapy exposure. Early analyses suggest specific genotypical changes according to tumor subtype and/or metastatic site. Extended and updated results will be reported at the meeting.
Citation Format: Cottu PH, Boulai A, Callens C, Baulande S, Legoix-Ne P, Bernard V, Vincent-Salomon A, Benhamo V, Brain EGC, Chemlali W, Campone M, Bachelot TD, Giacchetti S, Bonneterre J, Bidard F-C, Servois V, Comte A, Belin L, Sigal B, Bièche I. Comparison of mutational landscapes of primary breast cancer and first metastatic relapse: Results from the ESOPE study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr PD1-06.
Collapse
Affiliation(s)
- PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Boulai
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Baulande
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - P Legoix-Ne
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Bernard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Vincent-Salomon
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Benhamo
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - EGC Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - W Chemlali
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - M Campone
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - TD Bachelot
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - S Giacchetti
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - J Bonneterre
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - B Sigal
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Institut de Cancerologie de l'Ouest, Saint Herblain, France; Centre Leon Berard, Lyon, France; CHU Saint Louis, Paris, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
43
|
Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Abstract P1-10-17: Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-10-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose/Objectives
The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT).
Materials/Methods
Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during RT, 12 months and 36 months after its completion.
Results
Sixty-four patients were included from october 2007 to august 2010. They all received adjuvant RT and BV concomitant treatment, plus neo-adjuvant BV for 24 patients. RT was adjuvant and normo-fractionated. Twelve months toxicity was available for 60 patients and 36 months toxicity was available for 43 patients. Median follow-up was 46 months (18-77). Median age was 51 years old (23-68). Among 63 evaluated patients during RT, acute radiation dermatitis was observed in 48 (76%) patients : Grade 1 for 27 (43%), grade 2 for 17 (27%), grade 3 for 4 patients (6%). Grade 2 acute oesophagitis was observed in 1 patient. At 3 years, few toxicities were observed : 6 patients (14%) had grade 1 pain, 4 (9%) had grade 1 fibrosis, one (2%) had grade 1 telangiectasis, one (2%) had grade 1 paresis, 3 (7%) had grade 1 lymphoedema and one grade 3 lymphoedema. No grade 4 toxicity was observed. At 12 months, only one evaluated patient had a LVEF <50% and none at 36 months.
Conclusions
Concurrent bevacizumab with locoregional RT is associated with acceptable early and late 3-years toxicities in patients with BC. Determination of late toxicity at 60 months is currently underway.
Citation Format: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-17.
Collapse
Affiliation(s)
- A Dautruche
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - L Belin
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Cottu
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Bontemps
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Lemanski
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - B De La Lande
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - P Baumann
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Missohou
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - C Levy
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - K Peignaux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Reynaud-Bougnoux
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - F Denis
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Gobillion
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - N Ady Vago
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - A Fourquet
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| | - Y Kirova
- Institut Curie, Paris, France; CHU Jean Minjoz, Besançon, Doubs, France; Institut Régional du Cancer de Montpellier, Montpellier, Hérault, France; Institut Curie, Rene Huguenin Hospital, Saint-Cloud, Hauts-de-Seine, France; Centre d'Oncologie de Gentilly, Nancy, Meurthe-et-Moselle, France; Centre Henri Becquerel, Rouen, Seine-Maritime, France; Centre François Baclesse, Caen, Calvados, France; Centre Georges-François Leclerc, Dijon, Côte-d'Or, France; CHU Tours, Tours, Indre-et-Loire; Centre Jean Bernard, le Mans, Sarthe, France; Roche SAS, Boulogne-Billancourt, Hauts-de-Seine
| |
Collapse
|
44
|
Pierga JY, Riva F, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Bidard FC. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple negative breast cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Pivot X, Spano JP, Marc E, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkamoun C, Dima-Martinez L, Esposito N, Gligorov J. Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.53] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Rouzier R, Gouy S, Selle F, Lambaudie E, Guyon F, Fourchotte V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F. Complete resection rate at interval debulking surgery after bevacizumab containing neoadjuvant therapy: primary objective of the ANTHALYA trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw374.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A, L'Haridon T, Cottu P, Abadie-Lacourtoisie S, You B, Mousseau M, Dauba J, Del Piano F, Desmoulins I, Coussy F, Madranges N, Grenier J, Bidard FC, Proudhon C, MacGrogan G, Orsini C, Pulido M, Gonçalves A. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 2016; 27:812-8. [PMID: 27052658 DOI: 10.1093/annonc/mdw067] [Citation(s) in RCA: 193] [Impact Index Per Article: 24.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 02/08/2016] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Several expression array studies identified molecular apocrine breast cancer (BC) as a subtype that expresses androgen receptor (AR) but not estrogen receptor α. We carried out a multicentre single-arm phase II trial in women with AR-positive, estrogen, progesterone receptor and HER2-negative (triple-negative) metastatic or inoperable locally advanced BC to assess the efficacy and safety of abiraterone acetate (AA) plus prednisone. PATIENTS AND METHODS Patients with a metastatic or locally advanced, centrally reviewed, triple-negative and AR-positive (≥10% by immunohistochemistry, IHC) BC were eligible. Any number of previous lines of chemotherapy was allowed. AA (1000 mg) was administered once a day with prednisone (5 mg) twice a day until disease progression or intolerance. The primary end point was clinical benefit rate (CBR) at 6 months defined as the proportion of patients presenting a complete response (CR), partial response (PR) or stable disease (SD) ≥6 months. Secondary end points were objective response rate (ORR), progression-free survival (PFS) and safety. RESULTS One hundred and forty-six patients from 27 centres consented for IHC central review. Of the 138 patients with sufficient tissue available, 53 (37.6%) were AR-positive and triple-negative, and 34 of them were included from July 2013 to December 2014. Thirty patients were eligible and evaluable for the primary end point. The 6-month CBR was 20.0% [95% confidence interval (CI) 7.7%-38.6%], including 1 CR and 5 SD ≥6 months, 5 of them still being under treatment at the time of analysis (6.4+, 9.2+, 14.5+, 17.6+, 23.4+ months). The ORR was 6.7% (95% CI 0.8%-22.1%). The median PFS was 2.8 months (95% CI 1.7%-5.4%). Fatigue, hypertension, hypokalaemia and nausea were the most common drug-related adverse events; the majority of them being grade 1 or 2. CONCLUSIONS AA plus prednisone treatment is beneficial for some patients with molecular apocrine tumours and five patients are still on treatment. CLINICALTRIALSGOV NCT01842321.
Collapse
Affiliation(s)
- H Bonnefoi
- Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM U916, INSERM CIC1401, Bordeaux
| | - T Grellety
- Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM U916, INSERM CIC1401, Bordeaux
| | - O Tredan
- Department of Medical Oncology, Centre Léon Bérard, Lyon
| | - M Saghatchian
- Department of Medical Oncology, Breast Cancer Unit, Gustave Roussy, Villejuif
| | - F Dalenc
- Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse
| | - A Mailliez
- Department of Breast Cancer, Centre Oscar Lambret, Lille
| | - T L'Haridon
- Department of Medical Oncology, Centre Hospitalier Départemental Vendée, La Roche sur Yon
| | - P Cottu
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris
| | | | - B You
- Department of Medical Oncology, Teaching Hospital, Lyon-Sud University, Lyon
| | - M Mousseau
- Department of Medical Oncology, CHU Grenoble, Grenoble
| | - J Dauba
- Department of Medical Oncology, Centre Hospitalier Layné, Mont-de-Marsan
| | - F Del Piano
- Department of Gynecologic Surgery, Hôpital du Leman, Thonon-Les-Bains
| | - I Desmoulins
- Department of Medical Oncology, Centre GF Leclerc, Dijon
| | - F Coussy
- Department of Medical Oncology, Institut Curie, St Cloud
| | - N Madranges
- Department of Medical Oncology, Institut Bergonié Unicancer, Univ. Bordeaux, INSERM U916, INSERM CIC1401, Bordeaux
| | - J Grenier
- Department of Medical Oncology, Institut Sainte-Catherine, Avignon
| | - F C Bidard
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris
| | - C Proudhon
- Department of Medical Oncology, Institut Curie, PSL Research University, Paris
| | - G MacGrogan
- Department of Pathology, Institut Bergonié, INSERM U916, Bordeaux
| | | | - M Pulido
- Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC1401, Bordeaux
| | - A Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Cancer Research Center of Marseille, INSERM U7258, CNRS U1068, Aix-Marseille Université, Marseille, France
| |
Collapse
|
48
|
Bidard FC, Romieu G, Jacot W, Cottu P, Dieras V, Lerebours F, Servent V, Luporsi E, Lortholary A, Tubiana-Mathieu N, Espie M, Bollet M, Bourgeois H, Renaud N, Pelissier S, Armanet S, Baeten K, Pierga JY. Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-02-17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Liquid biopsy can reassess key therapeutic targets in metastatic breast cancer. Several studies showed that a low albeit significant rate of metastatic breast cancer initially considered as HER2-negative can be reclassified as HER2-positive by systematic biopsy procedures. We report here the current status of the CirCe T-DM1 trial [NCT01975142] which aims to demonstrate the clinical utility of HER2 status reassessment on circulating tumor cells (CTCs).
Methods: The first step of the trial consists in CTC count and HER2/CEP17 FISH on detected CTCs (CellSearch, Janssen Diagnostics) in patients (pts) with measurable disease progressing after the second line of chemotherapy. Pts with amplified CTCs (HER2/CEP17 ratio equal or higher than 2.2) are eligible to the treatment step of the study in two distinct cohorts: low CTC count (1 or 2 HER2-amplified CTCs) and high CTC count (3 and more HER2-amplified CTCs). In the treatment step has a Simon's two stage design, the anti-HER2 antibody-drug conjugate T-DM1 being administered until tumor progression. The primary objective of the trial is the confirmed response rate (RECIST). This trial is supported by Roche.
Results: CirCe T-DM1 has been initiated in 10 centers in France. As of June 2015, 105 metastatic breast cancers pts considered as HER2-negative were screened. 29 pts (27%) had no CTC detected, 68 pts (65%) had at least 1 CTC detected with no HER2 amplification, and 8 pts (8%) exhibited HER2-amplified CTCs. Among the 8 pts, 1 pt had 5 HER2-amplified CTC, 2 pts had 2 HER2-amplified CTC and 5 pts had 1 HER2-amplified CTC. HER2/CEP17 ratios among HER2-amplified CTCs ranged from 2.5 to 7. Five of the 8 pts were treated by T-DM1. One objective confirmed partial tumor response has been observed (20%).
Conclusion: The accrual is ongoing; the first efficacy assessment will occur after having treated 14 pts. This innovative trial highlights the promise and the complexity of liquid biopsy-based programs in the era of precision medicine: scarcity of the target, reliability and reproducibility of the target assessment, major efficacy when the target is matched to the appropriate drug.
Citation Format: Bidard F-C, Romieu G, Jacot W, Cottu P, Dieras V, Lerebours F, Servent V, Luporsi E, Lortholary A, Tubiana-Mathieu N, Espie M, Bollet M, Bourgeois H, Renaud N, Pelissier S, Armanet S, Baeten K, Pierga J-Y. T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-02-17.
Collapse
Affiliation(s)
- F-C Bidard
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - G Romieu
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - W Jacot
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - P Cottu
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - V Dieras
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - F Lerebours
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - V Servent
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - E Luporsi
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - A Lortholary
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - N Tubiana-Mathieu
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - M Espie
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - M Bollet
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - H Bourgeois
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - N Renaud
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - S Pelissier
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - S Armanet
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - K Baeten
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| | - J-Y Pierga
- Institut Curie, Paris, France; Institut du Cancer de Montpellier, Montpellier, France; Centre Oscar Lambret, Lille, France; Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France; Centre Catherine de Sienne, Nantes, France; Limoges University Hospital, Limoges, France; Saint Louis University Hospital, Paris, France; Institut de Cancerologie Hartmann, Levallois-Perret, France; Clinique Victor Hugo, Le Mans, France; Janssen Diagnostics, Beerse, Belgium
| |
Collapse
|
49
|
Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard FC, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Abstract P2-05-06: Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-05-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Cumulative evidence for phenotypic and molecular heterogeneity between primary breast cancer (BC) site and matched metastasis (mets) has been obtained in retrospective studies. Current expert consensus suggests performing biopsies of mets, but clinical utility and cost are unknown. The primary objective of the ESOPE study (NCT01956552) was to compare the phenotype and genotype of the primary tumor (PT) with those of matched mets at time of first distant relapse, before the start of any treatment, in order to optimize the treatment of mets
PATIENTS and METHODS: Between Nov. 2010 and Sept. 2013, we conducted a prospective multicenter study on BC patients (pts) with diagnosis of first mets. All pts were to have available Formalin-Fixed Paraffin-Embedded (FFPE) PT sample and mets accessible to either percutaneous or surgical sampling. All tissue samples were centrally analyzed with immunohistochemistry (ER, PgR, HER2, and Ki67) and FISH when indicated. Frozen samples were stored for further analyses. We recorded intended therapeutic decision before and after biopsy.
RESULTS: Of 93 pts included, 89 were eligible for biopsy. Median age was 57 years (28-81); median interval between PT and mets was 42 months (0-211), including 14 pts with novo metastatic breast cancer. Mets biopsy was performed in 85 pts (96%, refusal n=2, not feasible n=2). Toxicity was limited to only 1 grade 1 hemorrhage. Sampled sites were liver (44%), lung (16%), bone (13%), lymph node (13%), skin/muscle/chest wall (9%), ovary/peritoneum (4%), and adrenal gland (1%). PT was not available in 4 pts; mets biopsy was non contributive in 6 pts but led to a diagnosis of second primary cancer in 3 pts.
In 72 pts with matched PT and mets, PT were luminal A (n=11), luminal B (n=33), triple negative (n=13), HER2 (n=13), non-evaluable (n=2). Mets were luminal A (n=6), luminal B (n=30), triple negative (n=16), HER2 (n=14), non-evaluable (n=6). Discrepancy rates were: ER 18% [kappa for concordance =0.6, CI 95 % (0.42-0.77)], PgR: 39% [kappa=0.19, CI 95% (0.01-0.39)], Her2: 4% [kappa=0.86, CI 95% (0.7-1)], Ki67: 25% [kappa=0.19, CI 95% (-0.09; 0.49)].
The most frequent discrepancy rate was observed in pts with lum A PT, as only 3/10 developed Lum A mets. HER2 and triple negative were the most stable subtypes (12/13 and 12/12 respectively). Most importantly, mets biopsy led to a change in therapeutic decision in 25 pts (independent evaluation by 2 oncologists). Additional comparative targeted NGS analyses are ongoing on a first subset of 54 FFPE paired samples, and parallel whole exome sequencing is planned on 38 paired samples with available constitutional DNA.
CONCLUSION: Comparative analysis of breast cancer PT and first mets is routinely feasible, with very low morbidity and a significant impact for patients' management: 29% had a second cancer diagnosis or were proposed a therapeutic change. Furthermore, this study will provide additional data on quality and quantity of tissue available for molecular analysis, and ultimately in terms of cost-efficacy.
Citation Format: Comte A, Sigal-Zafrani B, Belin L, Bièche I, Callens C, Diéras V, Bidard F-C, Mariani O, Servois V, Szwarc D, Vincent-Salomon A, Brain ECG, Cottu PH. Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-05-06.
Collapse
Affiliation(s)
- A Comte
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - B Sigal-Zafrani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - L Belin
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - I Bièche
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - C Callens
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Diéras
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - F-C Bidard
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - O Mariani
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - V Servois
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - D Szwarc
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | | | - ECG Brain
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| | - PH Cottu
- Institut Curie, Paris, France; Institut Curie, Saint Cloud, France
| |
Collapse
|
50
|
Ng CKY, Bidard FC, Piscuoglio S, Lim RS, Pierga JY, Cottu P, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Reis-Filho JS. Abstract P2-01-02: Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The analysis of cell-free tumor DNA (ctDNA) from plasma has been heralded as a non-invasive technique for disease monitoring and as a means to overcome the challenges posed by intra-tumor genetic heterogeneity. ctDNA levels have been shown to correlate with tumor burden in breast cancer patients. Hence, we sought to define whether massively parallel sequencing of cell-free plasma DNA would capture the entire repertoire of somatic mutations present in the primary tumors and/ or metastases from patients with oligometastatic breast cancer.
Methods: Frozen diagnostic biopsies from primary tumors and their distant metastases were obtained from five prospectively accrued treatment-naïve patients with stage IV breast cancer at presentation (1 estrogen receptor (ER)+/HER2+, 2 ER+/HER2-, 2 ER-/HER2+). A second, independent formalin-fixed paraffin-embedded (FFPE) diagnostic biopsy was obtained from the primary tumor and metastasis from 4 patients. Plasma samples were obtained from all patients. DNA samples from microdissected frozen tumors and peripheral blood, as well as plasma from one patient, were subjected to high-depth whole exome sequencing. DNA samples from all biopsies (frozen/FFPE), plasma and peripheral blood were subjected to targeted capture massively parallel sequencing, with baits for all somatic mutations detected by whole exome sequencing and all exons of the 100 genes most frequently mutated in breast cancer. Driver mutations were defined by state-of-the-art bioinformatic methods and literature search.
Results: We identified and confirmed a median of 54 (range 25-75) and 53 (range 26-85) non-synonymous mutations in the primary tumors and metastases from the 5 cases analyzed, respectively. By sequencing the plasma DNA to a median depth of 248x (range 92-431x), state-of-the-art mutation callers revealed 0-4 mutations (0%-8% of mutations) per patient, and direct interrogation of the sequencing data, based on prior knowledge of the mutations present in the lesions, resulted in the identification of 2-18 mutations (3%-38% of mutations) per patient. Of the bona fide driver mutations, 2/3 TP53 mutations, 0/1 PIK3CA hotspot mutation, 0/1 BRCA2 frameshift mutation, 0/1 GATA3 frameshift mutation and 0/1 ERBB3 activating mutation were captured in the plasma DNA. A SMAD4 pathogenic mutation and a TCF7L2 truncating mutation were found in two diagnostic biopsies of metastatic lesions but not in two biopsies of the primary tumors in one patient each. Whilst the SMAD4 mutation was detected in the plasma DNA from the respective patient, the TCF7L2 mutation was not. Of the 62 mutations restricted to the primary tumors (0-42 per patient) and 74 restricted to the metastatic tumors (1-41 per patient), 4 and 7, respectively, were captured in the plasma DNA.
Conclusions: Massively parallel sequencing assessment of plasma DNA allows for the identification of mutations found in primary tumors and/ or their metastases, however, only a subset of these could be detected at up to 431x depth. These observations suggest that current approaches for whole exome or targeted massively parallel sequencing may not be sufficient to capture the genetic heterogeneity of breast cancers in patients with oligometastatic disease.
Citation Format: Ng CKY, Bidard F-C, Piscuoglio S, Lim RS, Pierga J-Y, Cottu P, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity in cell-free plasma DNA from patients with oligometastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-01-02.
Collapse
Affiliation(s)
- CKY Ng
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - F-C Bidard
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - S Piscuoglio
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - RS Lim
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - J-Y Pierga
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - P Cottu
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - A Vincent-Salomon
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - A Viale
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - L Norton
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - B Sigal
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, NY
| |
Collapse
|